|
G |
Ace |
angiotensin I converting enzyme |
decreases expression |
ISO |
1,10-phenanthroline results in decreased expression of ACE mRNA |
CTD |
PMID:19502547 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Ahr |
aryl hydrocarbon receptor |
decreases activity multiple interactions |
EXP ISO |
1,10-phenanthroline results in decreased activity of AHR protein [copper(II) nitrate binds to 1,10-phenanthroline binds to Quinolones] which results in increased activity of AHR protein; resveratrol inhibits the reaction [[copper(II) nitrate binds to 1,10-phenanthroline binds to Quinolones] which results in increased activity of AHR protein] 1,10-phenanthroline inhibits the reaction [Tetrachlorodibenzodioxin binds to AHR protein]; 1,10-phenanthroline inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CYP1A1 enhancer]]; Zinc inhibits the reaction [1,10-phenanthroline results in decreased activity of AHR protein] |
CTD |
PMID:1322109 PMID:2160969 PMID:27180721 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Ak1 |
adenylate kinase 1 |
decreases expression |
ISO |
1,10-phenanthroline results in decreased expression of AK1 mRNA |
CTD |
PMID:19502547 |
|
NCBI chr 3:15,912,431...15,923,045
Ensembl chr 3:15,912,485...15,923,041
|
|
G |
Akap9 |
A-kinase anchoring protein 9 |
increases expression |
ISO |
1,10-phenanthroline results in increased expression of AKAP9 mRNA |
CTD |
PMID:19502547 |
|
NCBI chr 4:30,056,738...30,192,716
Ensembl chr 4:30,056,738...30,192,606
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
decreases activity |
ISO |
1,10-phenanthroline results in decreased activity of AKR1C1 protein |
CTD |
PMID:8573067 PMID:12604236 |
|
NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
decreases activity |
ISO |
1,10-phenanthroline results in decreased activity of AKR1C2 protein |
CTD |
PMID:12604236 |
|
NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
decreases activity |
ISO |
1,10-phenanthroline results in decreased activity of AKR1C3 protein |
CTD |
PMID:12604236 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Aldoa |
aldolase, fructose-bisphosphate A |
increases expression |
ISO |
1,10-phenanthroline results in increased expression of ALDOA mRNA |
CTD |
PMID:19502547 |
|
NCBI chr 1:181,402,275...181,407,476
Ensembl chr 1:181,402,275...181,406,182
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
increases expression |
ISO |
1,10-phenanthroline results in increased expression of ALDOC mRNA |
CTD |
PMID:19502547 |
|
NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066
|
|
G |
Ankrd37 |
ankyrin repeat domain 37 |
increases expression |
ISO |
1,10-phenanthroline results in increased expression of ANKRD37 mRNA |
CTD |
PMID:19502547 |
|
NCBI chr16:46,269,025...46,271,971
Ensembl chr16:46,268,443...46,271,963
|
|
G |
Anpep |
alanyl aminopeptidase, membrane |
decreases activity multiple interactions |
ISO |
1,10-phenanthroline results in decreased activity of ANPEP protein Edetic Acid promotes the reaction [1,10-phenanthroline results in decreased activity of ANPEP protein] |
CTD |
PMID:17109655 |
|
NCBI chr 1:133,767,332...133,810,137
Ensembl chr 1:133,767,332...133,785,789
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
decreases expression |
ISO |
1,10-phenanthroline results in decreased expression of AQP3 mRNA |
CTD |
PMID:19641517 |
|
NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720
|
|
G |
Aspa |
aspartoacylase |
decreases activity |
ISO |
1,10-phenanthroline results in decreased activity of ASPA protein |
CTD |
PMID:17027983 |
|
NCBI chr10:57,891,704...57,945,267
Ensembl chr10:57,892,104...57,945,272
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions |
ISO |
[1,10-phenanthroline results in decreased activity of MBTPS2 protein] which affects the localization of ATF6 protein; [1,10-phenanthroline results in decreased activity of MBTPS2 protein] which results in decreased cleavage of ATF6 protein |
CTD |
PMID:21355074 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Bnip3l |
BCL2 interacting protein 3 like |
decreases expression |
ISO |
1,10-phenanthroline results in decreased expression of BNIP3L mRNA |
CTD |
PMID:19502547 |
|
NCBI chr15:41,174,594...41,197,730
Ensembl chr15:41,174,594...41,197,803
|
|
G |
Car9 |
carbonic anhydrase 9 |
increases expression |
ISO |
1,10-phenanthroline results in increased expression of CA9 mRNA |
CTD |
PMID:19502547 |
|
NCBI chr 5:57,763,234...57,769,838
Ensembl chr 5:57,763,206...57,769,838
|
|
G |
Cat |
catalase |
decreases expression |
ISO |
1,10-phenanthroline results in decreased expression of CAT mRNA |
CTD |
PMID:19502547 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cd83 |
CD83 molecule |
increases expression |
ISO |
1,10-phenanthroline results in increased expression of CD83 mRNA |
CTD |
PMID:19641517 |
|
NCBI chr17:20,887,309...20,907,009
Ensembl chr17:20,887,309...20,907,083
|
|
G |
Cd86 |
CD86 molecule |
increases expression multiple interactions |
ISO |
1,10-phenanthroline results in increased expression of CD86 mRNA Acetylcysteine inhibits the reaction [1,10-phenanthroline results in increased expression of CD86 mRNA]; SB 203580 inhibits the reaction [1,10-phenanthroline results in increased expression of CD86 mRNA] |
CTD |
PMID:19641517 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cftr |
CF transmembrane conductance regulator |
increases activity |
ISO |
1,10-phenanthroline results in increased activity of CFTR protein |
CTD |
PMID:15921678 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases stability |
ISO EXP |
1,10-phenanthroline inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]; [1,10-phenanthroline co-treated with cupric chloride] inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]; [1,10-phenanthroline co-treated with cupric chloride] inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]; ferric chloride inhibits the reaction [1,10-phenanthroline inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]]; zinc chloride inhibits the reaction [1,10-phenanthroline inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]] [copper(II) nitrate binds to 1,10-phenanthroline binds to Quinolones] which results in increased expression of CYP1A1 mRNA 1,10-phenanthroline inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CYP1A1 enhancer]] 1,10-phenanthroline results in increased stability of CYP1A1 mRNA |
CTD |
PMID:1322109 PMID:19896525 PMID:27180721 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Egln1 |
egl-9 family hypoxia-inducible factor 1 |
increases expression |
ISO |
1,10-phenanthroline results in increased expression of EGLN1 mRNA |
CTD |
PMID:19502547 |
|
NCBI chr19:52,867,914...52,907,169
Ensembl chr19:52,869,486...52,907,777
|
|
G |
Egln2 |
egl-9 family hypoxia-inducible factor 2 |
decreases expression |
ISO |
1,10-phenanthroline results in decreased expression of EGLN2 mRNA |
CTD |
PMID:19502547 |
|
NCBI chr 1:82,451,554...82,459,809
Ensembl chr 1:82,451,555...82,459,751
|
|
G |
Egr1 |
early growth response 1 |
increases expression |
ISO |
1,10-phenanthroline results in increased expression of EGR1 mRNA |
CTD |
PMID:19502547 |
|
NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Eno1 |
enolase 1 |
increases expression |
ISO |
1,10-phenanthroline results in increased expression of ENO1 mRNA |
CTD |
PMID:19502547 |
|
NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336
|
|
G |
Eno2 |
enolase 2 |
increases expression |
ISO |
1,10-phenanthroline results in increased expression of ENO2 mRNA |
CTD |
PMID:19502547 |
|
NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980
|
|
G |
Ercc2 |
ERCC excision repair 2, TFIIH core complex helicase subunit |
decreases expression |
ISO |
1,10-phenanthroline results in decreased expression of ERCC2 mRNA |
CTD |
PMID:19502547 |
|
NCBI chr 1:79,033,342...79,047,102
Ensembl chr 1:79,033,326...79,047,102
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
increases expression |
ISO |
1,10-phenanthroline results in increased expression of GAPDH mRNA |
CTD |
PMID:19502547 |
|
NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
decreases expression |
ISO |
1,10-phenanthroline results in decreased expression of GPX3 mRNA |
CTD |
PMID:19502547 |
|
NCBI chr10:39,028,624...39,036,695
Ensembl chr10:39,028,570...39,037,035
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
ISO |
[Copper binds to phthalic acid binds to 1,10-phenanthroline] which results in increased expression of H2AX protein modified form |
CTD |
PMID:22659117 |
|
NCBI chr 8:44,671,927...44,673,257
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
decreases expression |
ISO |
1,10-phenanthroline results in decreased expression of HAMP mRNA |
CTD |
PMID:25633564 |
|
NCBI chr 1:86,170,926...86,172,865
Ensembl chr 1:86,170,901...86,172,891
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
increases expression |
ISO |
1,10-phenanthroline results in increased expression of HBEGF mRNA |
CTD |
PMID:26800359 |
|
NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions increases activity |
ISO |
4'-O-methylalpinumisoflavone inhibits the reaction [1,10-phenanthroline deficiency results in increased activity of HIF1A protein]; alpinumisoflavone inhibits the reaction [1,10-phenanthroline deficiency results in increased activity of HIF1A protein] HIF1A protein promotes the reaction [1,10-phenanthroline results in increased expression of VEGFA protein] 1,10-phenanthroline results in increased activity of HIF1A protein |
CTD |
PMID:19091749 PMID:19502547 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hif3a |
hypoxia inducible factor 3 subunit alpha |
decreases expression |
ISO |
1,10-phenanthroline results in decreased expression of HIF3A mRNA |
CTD |
PMID:19502547 |
|
NCBI chr 1:77,718,110...77,750,448
Ensembl chr 1:77,722,471...77,749,758
|
|
G |
Hilpda |
hypoxia inducible lipid droplet-associated |
increases expression |
ISO |
1,10-phenanthroline results in increased expression of HILPDA mRNA |
CTD |
PMID:19502547 |
|
NCBI chr 4:57,871,076...57,875,206
Ensembl chr 4:57,871,110...57,874,557
|
|
G |
Hk1 |
hexokinase 1 |
increases expression |
ISO |
1,10-phenanthroline results in increased expression of HK1 mRNA |
CTD |
PMID:19502547 |
|
NCBI chr20:30,230,488...30,332,161
Ensembl chr20:30,230,486...30,332,131
|
|
G |
Hk2 |
hexokinase 2 |
increases expression |
ISO |
1,10-phenanthroline results in increased expression of HK2 mRNA |
CTD |
PMID:19502547 |
|
NCBI chr 4:115,234,509...115,283,530
Ensembl chr 4:115,234,509...115,283,530
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
1,10-phenanthroline inhibits the reaction [9,10-phenanthrenequinone results in decreased expression of HMOX1 protein]; 1,10-phenanthroline inhibits the reaction [Cadmium Chloride results in increased expression of HMOX1 mRNA]; 1,10-phenanthroline inhibits the reaction [Hydrogen Peroxide results in increased expression of HMOX1 mRNA]; 1,10-phenanthroline inhibits the reaction [Oxygen results in increased expression of HMOX1 mRNA]; 1,10-phenanthroline inhibits the reaction [Raloxifene Hydrochloride results in increased expression of HMOX1 mRNA]; 1,10-phenanthroline inhibits the reaction [sodium arsenite results in increased expression of HMOX1 mRNA] |
CTD |
PMID:9747510 PMID:15629867 PMID:20888885 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
1,10-phenanthroline affects the reaction [Smoke results in increased expression of ICAM1 protein] |
CTD |
PMID:15560890 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Igfbp5 |
insulin-like growth factor binding protein 5 |
decreases degradation |
EXP |
1,10-phenanthroline results in decreased degradation of IGFBP5 protein |
CTD |
PMID:8894652 |
|
NCBI chr 9:74,452,371...74,464,953
Ensembl chr 9:74,448,382...74,465,156
|
|
G |
Il1r1 |
interleukin 1 receptor type 1 |
decreases expression |
ISO |
1,10-phenanthroline results in decreased expression of IL1R1 mRNA |
CTD |
PMID:19502547 |
|
NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937
|
|
G |
Lamc2 |
laminin subunit gamma 2 |
multiple interactions |
ISO |
1,10-phenanthroline inhibits the reaction [Mustard Gas results in increased degradation of LAMC2 protein] |
CTD |
PMID:18095945 |
|
NCBI chr13:65,284,664...65,344,200
Ensembl chr13:65,284,664...65,344,200
|
|
G |
Ldha |
lactate dehydrogenase A |
increases expression |
ISO |
1,10-phenanthroline results in increased expression of LDHA mRNA |
CTD |
PMID:19502547 |
|
NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472
|
|
G |
Mbtps2 |
membrane-bound transcription factor peptidase, site 2 |
multiple interactions |
ISO |
[1,10-phenanthroline results in decreased activity of MBTPS2 protein] which affects the localization of ATF6 protein; [1,10-phenanthroline results in decreased activity of MBTPS2 protein] which affects the localization of SREBF1 protein; [1,10-phenanthroline results in decreased activity of MBTPS2 protein] which results in decreased cleavage of ATF6 protein; [1,10-phenanthroline results in decreased activity of MBTPS2 protein] which results in decreased cleavage of SREBF1 protein |
CTD |
PMID:21355074 |
|
NCBI chr X:37,410,914...37,461,130
Ensembl chr X:37,410,811...37,464,430
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
increases expression |
ISO |
1,10-phenanthroline results in increased expression of MDM2 mRNA |
CTD |
PMID:19502547 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Mif |
macrophage migration inhibitory factor |
increases expression |
ISO |
1,10-phenanthroline results in increased expression of MIF mRNA |
CTD |
PMID:19502547 |
|
NCBI chr20:12,790,919...12,791,784
Ensembl chr20:12,790,902...12,799,504
|
|
G |
Mmp8 |
matrix metallopeptidase 8 |
decreases activity |
ISO |
1,10-phenanthroline results in decreased activity of MMP8 protein |
CTD |
PMID:15057751 |
|
NCBI chr 8:4,724,009...4,732,956
Ensembl chr 8:4,724,029...4,733,520
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO EXP |
1,10-phenanthroline inhibits the reaction [PLAU protein results in increased activity of MMP9 protein] 1,10-phenanthroline inhibits the reaction [Adenosine Triphosphate results in increased activity of MMP9 protein] |
CTD |
PMID:20177776 PMID:20195827 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Nln |
neurolysin |
decreases activity |
EXP |
1,10-phenanthroline decreases activity of Nln protein |
RGD |
PMID:7836437 |
RGD:9831155 |
NCBI chr 2:35,133,634...35,232,927
Ensembl chr 2:35,134,145...35,232,914
|
|
G |
Nppb |
natriuretic peptide B |
increases expression |
ISO |
1,10-phenanthroline results in increased expression of NPPB mRNA |
CTD |
PMID:19502547 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Nub1 |
negative regulator of ubiquitin-like proteins 1 |
increases expression |
ISO |
1,10-phenanthroline results in increased expression of NUB1 mRNA |
CTD |
PMID:19502547 |
|
NCBI chr 4:10,442,917...10,473,689
Ensembl chr 4:10,442,917...10,473,694
|
|
G |
Ocln |
occludin |
multiple interactions |
ISO |
1,10-phenanthroline inhibits the reaction [Patulin results in increased degradation of OCLN protein] |
CTD |
PMID:19013514 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
P4ha2 |
prolyl 4-hydroxylase subunit alpha 2 |
increases expression |
ISO |
1,10-phenanthroline results in increased expression of P4HA2 mRNA |
CTD |
PMID:19502547 |
|
NCBI chr10:38,243,047...38,271,989
Ensembl chr10:38,243,139...38,287,314
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase 1 |
increases expression |
ISO |
1,10-phenanthroline results in increased expression of PDK1 mRNA |
CTD |
PMID:19502547 |
|
NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038
|
|
G |
Pdk3 |
pyruvate dehydrogenase kinase 3 |
increases expression |
ISO |
1,10-phenanthroline results in increased expression of PDK3 mRNA |
CTD |
PMID:19502547 |
|
NCBI chr X:58,477,471...58,553,932
Ensembl chr X:58,486,554...58,553,557
|
|
G |
Pgk1 |
phosphoglycerate kinase 1 |
increases expression |
ISO |
1,10-phenanthroline results in increased expression of PGK1 mRNA |
CTD |
PMID:19502547 |
|
NCBI chr X:71,271,454...71,287,429
Ensembl chr X:71,271,440...71,287,418
|
|
G |
Plau |
plasminogen activator, urokinase |
multiple interactions |
ISO |
1,10-phenanthroline inhibits the reaction [PLAU protein results in increased activity of MMP9 protein] |
CTD |
PMID:20177776 |
|
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Plod3 |
procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 |
increases expression |
ISO |
1,10-phenanthroline results in increased expression of PLOD3 mRNA |
CTD |
PMID:19502547 |
|
NCBI chr12:19,676,384...19,686,945
Ensembl chr12:19,676,386...19,686,960
|
|
G |
Ppp2r1b |
protein phosphatase 2 scaffold subunit A beta |
decreases expression |
ISO |
1,10-phenanthroline results in decreased expression of PPP2R1B mRNA |
CTD |
PMID:19502547 |
|
NCBI chr 8:51,195,860...51,228,442
Ensembl chr 8:51,186,717...51,228,485
|
|
G |
Psph |
phosphoserine phosphatase |
decreases expression |
ISO |
1,10-phenanthroline results in decreased expression of PSPH mRNA |
CTD |
PMID:19502547 |
|
NCBI chr12:26,882,524...26,905,084
Ensembl chr12:26,883,133...26,905,074
|
|
G |
Sele |
selectin E |
multiple interactions |
ISO |
1,10-phenanthroline affects the reaction [Smoke results in increased expression of SELE protein] |
CTD |
PMID:15560890 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Serpine1 |
serpin family E member 1 |
increases expression |
ISO |
1,10-phenanthroline results in increased expression of SERPINE1 mRNA |
CTD |
PMID:19502547 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
1,10-phenanthroline inhibits the reaction [9,10-phenanthrenequinone results in decreased expression of SOD1 protein]; 1,10-phenanthroline inhibits the reaction [[Hydrogen Peroxide co-treated with Nitroprusside] results in decreased expression of SOD1 protein] |
CTD |
PMID:15629867 PMID:20674559 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO |
1,10-phenanthroline inhibits the reaction [[Hydrogen Peroxide co-treated with Nitroprusside] results in increased expression of SOD2 protein] |
CTD |
PMID:20674559 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
[1,10-phenanthroline results in decreased activity of MBTPS2 protein] which affects the localization of SREBF1 protein; [1,10-phenanthroline results in decreased activity of MBTPS2 protein] which results in decreased cleavage of SREBF1 protein |
CTD |
PMID:21355074 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
1,10-phenanthroline inhibits the reaction [Hydrogen Peroxide affects the localization of STAT3 protein] |
CTD |
PMID:10364193 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tfrc |
transferrin receptor |
increases expression |
ISO |
1,10-phenanthroline results in increased expression of TFRC mRNA |
CTD |
PMID:19502547 |
|
NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257
|
|
G |
Timm17a |
translocase of inner mitochondrial membrane 17A |
multiple interactions |
ISO |
1,10-phenanthroline inhibits the reaction [Adenosine Triphosphate results in decreased expression of TIMM17A protein] |
CTD |
PMID:24315374 |
|
NCBI chr13:46,731,117...46,742,604
Ensembl chr13:46,730,660...46,742,655
|
|
G |
Tp53 |
tumor protein p53 |
affects folding |
ISO |
1,10-phenanthroline affects the folding of TRP53 protein |
CTD |
PMID:8467489 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression multiple interactions |
ISO |
1,10-phenanthroline results in increased expression of VEGFA mRNA; 1,10-phenanthroline results in increased expression of VEGFA protein HIF1A protein promotes the reaction [1,10-phenanthroline results in increased expression of VEGFA protein] |
CTD |
PMID:19502547 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Actb |
actin, beta |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of ACTB mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877
|
|
G |
Arhgdia |
Rho GDP dissociation inhibitor alpha |
multiple interactions |
ISO |
[pyrrolidine dithiocarbamic acid co-treated with bathocuproine sulfonate] results in increased expression of ARHGDIA mRNA |
CTD |
PMID:15477007 |
|
NCBI chr10:105,854,526...105,858,020
Ensembl chr10:105,854,533...105,858,023
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of ATF4 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atox1 |
antioxidant 1 copper chaperone |
multiple interactions |
ISO |
ATOX1 protein affects the reaction [[bathocuproine sulfonate results in decreased abundance of Copper] which results in decreased expression of SLC31A2 mRNA]; ATOX1 protein affects the reaction [[bathocuproine sulfonate results in decreased abundance of Copper] which results in decreased expression of SLC31A2 protein] |
CTD |
PMID:20194531 |
|
NCBI chr10:39,564,855...39,579,892
Ensembl chr10:39,564,857...39,579,950
|
|
G |
Atp7a |
ATPase copper transporting alpha |
multiple interactions |
ISO |
[Penicillamine co-treated with bathocuproine sulfonate] promotes the reaction [CLU protein binds to ATP7A protein]; bathocuproine sulfonate inhibits the reaction [ATP7A protein results in increased activity of TYR protein]; cupric chloride inhibits the reaction [bathocuproine sulfonate inhibits the reaction [ATP7A protein results in increased activity of TYR protein]] |
CTD |
PMID:11092760 PMID:21242307 |
|
NCBI chr X:71,094,144...71,201,550
Ensembl chr X:71,094,202...71,198,354
|
|
G |
Atp7b |
ATPase copper transporting beta |
multiple interactions |
ISO |
[Penicillamine co-treated with bathocuproine sulfonate] promotes the reaction [CLU protein binds to ATP7B protein] |
CTD |
PMID:21242307 |
|
NCBI chr16:69,952,286...70,024,404
Ensembl chr16:69,951,778...70,023,636
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
bathocuproine sulfonate results in decreased expression of BCL2 protein |
CTD |
PMID:24614111 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2a1 |
BCL2-related protein A1 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of BCL2A1 mRNA]; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of BCL2A1 mRNA]] |
CTD |
PMID:15477007 |
|
NCBI chr 8:89,716,914...89,724,998
Ensembl chr 8:89,716,914...89,724,998
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
bathocuproine sulfonate inhibits the reaction [[Copper binds to neocuproine] which results in increased activity of CASP3 protein]; bathocuproine sulfonate inhibits the reaction [[Disulfiram binds to cupric chloride] which results in increased activity of CASP3 protein]; bathocuproine sulfonate inhibits the reaction [[pyrrolidine dithiocarbamic acid co-treated with Copper] results in increased activity of CASP3 protein] |
CTD |
PMID:10941151 PMID:11239917 PMID:18056745 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CASP8 mRNA]; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CASP8 mRNA]] |
CTD |
PMID:15477007 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]] |
CTD |
PMID:11006087 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL3 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Cct5 |
chaperonin containing TCP1 subunit 5 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCT5 mRNA]; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCT5 mRNA]] |
CTD |
PMID:15477007 |
|
NCBI chr 2:82,591,750...82,602,903
Ensembl chr 2:82,590,630...82,602,930
|
|
G |
Cd200 |
Cd200 molecule |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD200 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr11:55,410,166...55,437,527
Ensembl chr11:55,410,196...55,501,648
|
|
G |
Cd44 |
CD44 molecule (Indian blood group) |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD44 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cdh17 |
cadherin 17 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CDH17 mRNA]; [pyrrolidine dithiocarbamic acid co-treated with bathocuproine sulfonate] results in increased expression of CDH17 mRNA |
CTD |
PMID:15477007 |
|
NCBI chr 5:25,262,820...25,314,884
Ensembl chr 5:25,262,758...25,314,884
|
|
G |
Clu |
clusterin |
multiple interactions |
ISO |
[Penicillamine co-treated with bathocuproine sulfonate] promotes the reaction [CLU protein binds to ATP7A protein]; [Penicillamine co-treated with bathocuproine sulfonate] promotes the reaction [CLU protein binds to ATP7B protein] |
CTD |
PMID:21242307 |
|
NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
|
|
G |
Cntnap1 |
contactin associated protein 1 |
multiple interactions |
ISO |
[pyrrolidine dithiocarbamic acid co-treated with bathocuproine sulfonate] results in increased expression of CNTNAP1 mRNA |
CTD |
PMID:15477007 |
|
NCBI chr10:86,109,850...86,125,612
Ensembl chr10:86,111,643...86,125,611
|
|
G |
Comt |
catechol-O-methyltransferase |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of COMT mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Cp |
ceruloplasmin |
multiple interactions |
ISO |
bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid promotes the reaction [[JUN protein binds to FOS protein] which results in increased expression of and results in increased activity of CP protein]]; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid results in increased expression of CP protein] |
CTD |
PMID:17032174 |
|
NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075
|
|
G |
Cpsf1 |
cleavage and polyadenylation specific factor 1 |
multiple interactions |
ISO |
[pyrrolidine dithiocarbamic acid co-treated with bathocuproine sulfonate] results in increased expression of CPSF1 mRNA |
CTD |
PMID:15477007 |
|
NCBI chr 7:108,319,429...108,330,023
Ensembl chr 7:108,319,434...108,329,934
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
[pyrrolidine dithiocarbamic acid co-treated with bathocuproine sulfonate] results in increased expression of CREB1 mRNA |
CTD |
PMID:15477007 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crem |
cAMP responsive element modulator |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CREM mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989
|
|
G |
Cul5 |
cullin 5 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CUL5 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 8:54,012,963...54,066,751
Ensembl chr 8:54,016,006...54,066,666
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
EXP |
bathocuproine sulfonate inhibits the reaction [[Copper binds to neocuproine] which affects the localization of CYCS protein] |
CTD |
PMID:18056745 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
|
|
G |
Dnajb1 |
DnaJ heat shock protein family (Hsp40) member B1 |
multiple interactions |
ISO |
[pyrrolidine dithiocarbamic acid co-treated with bathocuproine sulfonate] results in increased expression of DNAJB1 mRNA |
CTD |
PMID:15477007 |
|
NCBI chr19:24,522,717...24,526,458
Ensembl chr19:24,522,717...24,526,458
|
|
G |
Dusp4 |
dual specificity phosphatase 4 |
multiple interactions |
ISO |
bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of DUSP4 mRNA]] |
CTD |
PMID:15477007 |
|
NCBI chr16:57,376,659...57,398,161
Ensembl chr16:57,377,229...57,398,138
|
|
G |
Egr2 |
early growth response 2 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of EGR2 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562
|
|
G |
Egr3 |
early growth response 3 |
multiple interactions |
ISO |
[pyrrolidine dithiocarbamic acid co-treated with bathocuproine sulfonate] results in increased expression of EGR3 mRNA |
CTD |
PMID:15477007 |
|
NCBI chr15:45,150,335...45,156,052
Ensembl chr15:45,150,567...45,154,627
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
bathocuproine sulfonate inhibits the reaction [copper histidine results in increased expression of FASN mRNA] |
CTD |
PMID:24170205 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
ISO |
bathocuproine sulfonate inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]; bathocuproine sulfonate inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:22842628 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of FOS protein]]; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid promotes the reaction [[JUN protein binds to FOS protein] which results in increased expression of and results in increased activity of CP protein]] |
CTD |
PMID:15477007 PMID:17032174 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fyb1 |
FYN binding protein 1 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of FYB1 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 2:55,621,585...55,781,206
Ensembl chr 2:55,632,698...55,779,629
|
|
G |
Gfra2 |
GDNF family receptor alpha 2 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of GFRA2 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr15:45,941,841...46,033,715
Ensembl chr15:45,941,828...46,033,714
|
|
G |
Gnas |
GNAS complex locus |
multiple interactions |
ISO |
[pyrrolidine dithiocarbamic acid co-treated with bathocuproine sulfonate] results in increased expression of GNAS mRNA |
CTD |
PMID:15477007 |
|
NCBI chr 3:163,071,003...163,136,350
Ensembl chr 3:163,071,417...163,127,262 Ensembl chr 3:163,071,417...163,127,262
|
|
G |
Gtf2h2 |
general transcription factor IIH subunit 2 |
multiple interactions |
ISO |
[pyrrolidine dithiocarbamic acid co-treated with bathocuproine sulfonate] results in increased expression of GTF2H2C mRNA |
CTD |
PMID:15477007 |
|
NCBI chr 2:31,623,752...31,652,697
Ensembl chr 2:31,624,678...31,652,592
|
|
G |
Hadha |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HADHA mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 6:26,187,969...26,227,605
Ensembl chr 6:26,187,956...26,227,869
|
|
G |
Hck |
HCK proto-oncogene, Src family tyrosine kinase |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HCK mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 3:141,571,587...141,614,696
Ensembl chr 3:141,571,587...141,614,693
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
[Penicillamine co-treated with bathocuproine sulfonate] results in increased expression of HMOX1 protein |
CTD |
PMID:21242307 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnrnpul1 |
heterogeneous nuclear ribonucleoprotein U-like 1 |
multiple interactions |
ISO |
[pyrrolidine dithiocarbamic acid co-treated with bathocuproine sulfonate] results in increased expression of HNRNPUL1 mRNA |
CTD |
PMID:15477007 |
|
NCBI chr 1:81,228,404...81,264,121
Ensembl chr 1:81,228,404...81,262,592
|
|
G |
Hpx |
hemopexin |
multiple interactions |
ISO |
bathocuproine sulfonate inhibits the reaction [[cobaltiprotoporphyrin co-treated with HPX protein] affects the localization of MTF1 protein]; bathocuproine sulfonate inhibits the reaction [[cobaltiprotoporphyrin co-treated with HPX protein] results in increased expression of MTF1 mRNA]; bathocuproine sulfonate inhibits the reaction [[Heme co-treated with HPX protein] affects the localization of MTF1 protein] |
CTD |
PMID:11213479 |
|
NCBI chr 1:159,932,819...159,940,327
Ensembl chr 1:159,932,755...159,940,328
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
multiple interactions |
ISO |
[pyrrolidine dithiocarbamic acid co-treated with bathocuproine sulfonate] results in increased expression of HSPA8 mRNA; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HSPA8 mRNA]] |
CTD |
PMID:15477007 |
|
NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259
|
|
G |
Hyal3 |
hyaluronidase 3 |
multiple interactions |
ISO |
[pyrrolidine dithiocarbamic acid co-treated with bathocuproine sulfonate] results in increased expression of HYAL3 mRNA |
CTD |
PMID:15477007 |
|
NCBI chr 8:108,254,385...108,260,020
Ensembl chr 8:108,250,667...108,260,647
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]] |
CTD |
PMID:15477007 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il2ra |
interleukin 2 receptor subunit alpha |
multiple interactions |
ISO |
bathocuproine sulfonate inhibits the reaction [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein]] |
CTD |
PMID:23134680 |
|
NCBI chr17:66,849,974...66,898,665
Ensembl chr17:66,849,974...66,898,697
|
|
G |
Il2rb |
interleukin 2 receptor subunit beta |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RB mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 7:110,033,341...110,048,054
Ensembl chr 7:110,033,341...110,048,054
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid promotes the reaction [[JUN protein binds to FOS protein] which results in increased expression of and results in increased activity of CP protein]]; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN protein]] |
CTD |
PMID:15477007 PMID:17032174 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Lcp1 |
lymphocyte cytosolic protein 1 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of LCP1 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr15:50,443,300...50,544,682
Ensembl chr15:50,488,149...50,544,680
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions |
ISO |
bathocuproine sulfonate inhibits the reaction [copper histidine results in increased expression of LDLR mRNA] |
CTD |
PMID:24170205 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Ltbp4 |
latent transforming growth factor beta binding protein 4 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of LTBP4 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 1:82,600,136...82,634,346
Ensembl chr 1:82,600,136...82,632,178
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO EXP |
bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of MAPK1 protein]] bathocuproine sulfonate inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein] bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid results in decreased activity of MAPK1 protein] |
CTD |
PMID:10658192 PMID:15477007 PMID:22842628 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO EXP |
bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of MAPK3 protein]] bathocuproine sulfonate inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein] bathocuproine sulfonate inhibits the reaction [[pyrrolidine dithiocarbamic acid co-treated with Copper] results in increased activity of MAPK3 protein] |
CTD |
PMID:10941151 PMID:15477007 PMID:22842628 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
bathocuproine sulfonate inhibits the reaction [[Copper binds to neocuproine] which results in increased activity of MAPK8 protein]; bathocuproine sulfonate inhibits the reaction [[Disulfiram binds to cupric chloride] which results in increased activity of MAPK8 protein]; bathocuproine sulfonate inhibits the reaction [[pyrrolidine dithiocarbamic acid co-treated with Copper] results in increased activity of MAPK8 protein] |
CTD |
PMID:10941151 PMID:11239917 PMID:18056745 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mt1-ps3 |
metallothionein 1, pseudogene 3 |
multiple interactions |
ISO |
[pyrrolidine dithiocarbamic acid co-treated with bathocuproine sulfonate] results in increased expression of MT1E mRNA |
CTD |
PMID:15477007 |
|
NCBI chr17:74,786,652...74,787,040
Ensembl chr17:74,786,654...74,787,135
|
|
G |
Mta1 |
metastasis associated 1 |
multiple interactions |
ISO |
[pyrrolidine dithiocarbamic acid co-treated with bathocuproine sulfonate] results in increased expression of MTA1 mRNA |
CTD |
PMID:15477007 |
|
NCBI chr 6:132,178,608...132,217,641
Ensembl chr 6:132,178,853...132,217,641
|
|
G |
Mtf1 |
metal-regulatory transcription factor 1 |
multiple interactions |
ISO |
bathocuproine sulfonate inhibits the reaction [[cobaltiprotoporphyrin co-treated with HPX protein] affects the localization of MTF1 protein]; bathocuproine sulfonate inhibits the reaction [[cobaltiprotoporphyrin co-treated with HPX protein] results in increased expression of MTF1 mRNA]; bathocuproine sulfonate inhibits the reaction [[Heme co-treated with HPX protein] affects the localization of MTF1 protein] |
CTD |
PMID:11213479 |
|
NCBI chr 5:137,062,319...137,107,136
Ensembl chr 5:137,062,376...137,107,136
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of MYC mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Naa80 |
N(alpha)-acetyltransferase 80, NatH catalytic subunit |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of NAA80 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 8:108,254,314...108,257,564
Ensembl chr 8:108,253,302...108,257,563
|
|
G |
Nell1 |
neural EGFL like 1 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of NELL1 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 1:99,709,305...100,573,872
Ensembl chr 1:99,709,793...100,573,860
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
[pyrrolidine dithiocarbamic acid co-treated with bathocuproine sulfonate] results in increased expression of NFE2L2 mRNA |
CTD |
PMID:15477007 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [TNF protein results in increased activity of NFKB1 protein]] |
CTD |
PMID:11006087 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]] |
CTD |
PMID:11006087 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nmi |
N-myc (and STAT) interactor |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of NMI mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 3:36,415,607...36,439,716
Ensembl chr 3:36,415,607...36,439,498
|
|
G |
Nr4a3 |
nuclear receptor subfamily 4, group A, member 3 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of NR4A3 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 5:62,361,588...62,401,489
Ensembl chr 5:62,361,822...62,402,733
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
multiple interactions |
ISO |
[pyrrolidine dithiocarbamic acid co-treated with bathocuproine sulfonate] results in increased expression of ODC1 mRNA |
CTD |
PMID:15477007 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Pax8 |
paired box 8 |
multiple interactions |
EXP |
bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid results in decreased expression of PAX8 mRNA] |
CTD |
PMID:11108245 |
|
NCBI chr 3:7,185,721...7,242,363
Ensembl chr 3:7,185,723...7,242,363
|
|
G |
Pcna |
proliferating cell nuclear antigen |
decreases expression |
ISO |
bathocuproine sulfonate results in decreased expression of PCNA protein |
CTD |
PMID:24614111 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Ppp1r10 |
protein phosphatase 1, regulatory subunit 10 |
multiple interactions |
ISO |
[pyrrolidine dithiocarbamic acid co-treated with bathocuproine sulfonate] results in increased expression of PPP1R10 mRNA |
CTD |
PMID:15477007 |
|
NCBI chr20:2,822,995...2,838,125
Ensembl chr20:2,822,995...2,837,611
|
|
G |
Prnp |
prion protein |
multiple interactions |
EXP |
bathocuproine sulfonate inhibits the reaction [cupric chloride results in increased expression of PRNP protein] |
CTD |
PMID:16148034 |
|
NCBI chr 3:119,186,073...119,201,513
Ensembl chr 3:119,177,485...119,203,937
|
|
G |
Rel |
REL proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of REL mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr14:97,690,105...97,721,194
Ensembl chr14:97,695,161...97,720,892
|
|
G |
Sco1 |
synthesis of cytochrome C oxidase 1 |
increases oxidation |
ISO |
bathocuproine sulfonate results in increased oxidation of SCO1 protein |
CTD |
PMID:23345593 |
|
NCBI chr10:51,744,656...51,757,246
Ensembl chr10:51,744,656...51,757,237
|
|
G |
Sla |
src-like adaptor |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SLA mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 7:98,534,431...98,584,810
Ensembl chr 7:98,535,368...98,584,648
|
|
G |
Slc31a1 |
solute carrier family 31 member 1 |
multiple interactions |
ISO |
[bathocuproine sulfonate results in decreased abundance of Copper] which results in increased expression of SLC31A1 mRNA; bathocuproine sulfonate promotes the reaction [SP1 protein results in increased expression of SLC31A1 mRNA] |
CTD |
PMID:18483225 |
|
NCBI chr 5:75,814,744...75,844,241
Ensembl chr 5:75,814,743...75,844,228
|
|
G |
Slc31a2 |
solute carrier family 31 member 2 |
multiple interactions affects localization |
ISO |
[[bathocuproine sulfonate results in decreased abundance of Copper] which results in decreased expression of SLC31A2 protein] which results in increased uptake of and results in increased susceptibility to Cisplatin; [bathocuproine sulfonate results in decreased abundance of Copper] which results in decreased expression of SLC31A2 protein bathocuproine sulfonate affects the localization of SLC31A2 protein ATOX1 protein affects the reaction [[bathocuproine sulfonate results in decreased abundance of Copper] which results in decreased expression of SLC31A2 mRNA]; ATOX1 protein affects the reaction [[bathocuproine sulfonate results in decreased abundance of Copper] which results in decreased expression of SLC31A2 protein] |
CTD |
PMID:20194531 |
|
NCBI chr 5:75,738,008...75,748,542
Ensembl chr 5:75,738,024...75,748,542
|
|
G |
Snrnp70 |
small nuclear ribonucleoprotein U1 subunit 70 |
multiple interactions |
ISO |
[pyrrolidine dithiocarbamic acid co-treated with bathocuproine sulfonate] results in increased expression of SNRNP70 mRNA |
CTD |
PMID:15477007 |
|
NCBI chr 1:95,856,039...95,876,434
Ensembl chr 1:95,856,036...95,876,392
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
[pyrrolidine dithiocarbamic acid co-treated with bathocuproine sulfonate] results in increased expression of SOD1 mRNA |
CTD |
PMID:15477007 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sp1 |
Sp1 transcription factor |
multiple interactions |
ISO |
bathocuproine sulfonate promotes the reaction [SP1 protein results in increased expression of SLC31A1 mRNA] |
CTD |
PMID:18483225 |
|
NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961
|
|
G |
Srgn |
serglycin |
multiple interactions |
ISO |
[pyrrolidine dithiocarbamic acid co-treated with bathocuproine sulfonate] results in increased expression of SRGN mRNA |
CTD |
PMID:15477007 |
|
NCBI chr20:30,442,810...30,479,549
Ensembl chr20:30,442,813...30,457,406
|
|
G |
Srpra |
SRP receptor subunit alpha |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SRPRA mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 8:33,560,365...33,566,458
Ensembl chr 8:33,560,348...33,566,470
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [TNF protein results in increased activity of NFKB1 protein]]; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]]; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]] |
CTD |
PMID:11006087 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf1b |
TNF receptor superfamily member 1B |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TNFRSF1B mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 5:157,070,642...157,104,216
Ensembl chr 5:157,070,642...157,104,206
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
bathocuproine sulfonate inhibits the reaction [[pyrrolidine dithiocarbamic acid results in increased abundance of Copper] which results in increased oxidation of and results in increased expression of TP53 protein] |
CTD |
PMID:11964141 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tpo |
thyroid peroxidase |
multiple interactions |
EXP |
bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid results in decreased expression of TPO mRNA] |
CTD |
PMID:11108245 |
|
NCBI chr 6:46,698,402...46,768,199
Ensembl chr 6:46,698,414...46,768,199
|
|
G |
Traf1 |
TNF receptor-associated factor 1 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TRAF1 mRNA]; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TRAF1 mRNA]] |
CTD |
PMID:15477007 |
|
NCBI chr 3:18,222,024...18,242,163
Ensembl chr 3:18,222,054...18,241,807
|
|
G |
Tyr |
tyrosinase |
multiple interactions |
ISO |
bathocuproine sulfonate inhibits the reaction [ATP7A protein results in increased activity of TYR protein]; cupric chloride inhibits the reaction [bathocuproine sulfonate inhibits the reaction [ATP7A protein results in increased activity of TYR protein]] |
CTD |
PMID:11092760 |
|
NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207
|
|
G |
Tyrobp |
transmembrane immune signaling adaptor Tyrobp |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TYROBP mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 1:85,672,931...85,676,856
Ensembl chr 1:85,672,994...85,676,848
|
|
G |
Ube2l6 |
ubiquitin-conjugating enzyme E2L 6 |
multiple interactions |
ISO |
[pyrrolidine dithiocarbamic acid co-treated with bathocuproine sulfonate] results in increased expression of UBE2L6 mRNA |
CTD |
PMID:15477007 |
|
NCBI chr 3:69,873,025...69,888,042
Ensembl chr 3:69,873,424...69,888,048
|
|
G |
Ubl4a |
ubiquitin-like 4A |
multiple interactions |
ISO |
[pyrrolidine dithiocarbamic acid co-treated with bathocuproine sulfonate] results in increased expression of UBL4A mRNA |
CTD |
PMID:15477007 |
|
NCBI chr X:152,151,242...152,154,094
Ensembl chr X:152,151,460...152,154,069
|
|
G |
Vim |
vimentin |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of VIM mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
EXP |
BKM120 decreases expression of cyclin E protein in rat pituitary tumor cell line |
RGD |
PMID:26983879 |
RGD:152177690 |
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Prl |
prolactin |
decreases expression |
EXP |
BKM120 decreases expression of prolactin protein in serum of treated rats |
RGD |
PMID:26983879 |
RGD:152177690 |
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation |
ISO |
copanlisib results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:31445927 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Fas |
Fas cell surface death receptor |
affects response to substance |
ISO |
copanlisib affects the susceptibility to FAS protein |
CTD |
PMID:31445927 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Tnf |
tumor necrosis factor |
increases response to substance |
ISO |
copanlisib results in increased susceptibility to TNF protein |
CTD |
PMID:31445927 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
corilagin inhibits the reaction [Doxorubicin results in increased expression of AKT1 protein]; corilagin inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of AKT1 mRNA] |
CTD |
PMID:34605098 PMID:35103375 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
corilagin inhibits the reaction [Doxorubicin results in increased expression of BAX protein]; corilagin inhibits the reaction [Methylnitronitrosoguanidine results in decreased expression of BAX protein] |
CTD |
PMID:34605098 PMID:35103375 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
corilagin inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; corilagin inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of BCL2 protein] |
CTD |
PMID:34605098 PMID:35103375 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bsg |
basigin (Ok blood group) |
multiple interactions |
EXP |
corilagin inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of BSG mRNA] |
CTD |
PMID:35103375 |
|
NCBI chr 7:9,993,170...10,000,387
Ensembl chr 7:9,993,170...10,000,387
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
corilagin inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein]; corilagin inhibits the reaction [Methylnitronitrosoguanidine results in decreased expression of CASP3 protein] |
CTD |
PMID:34605098 PMID:35103375 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
corilagin inhibits the reaction [Methylnitronitrosoguanidine results in decreased expression of CASP9 protein] |
CTD |
PMID:35103375 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP ISO |
corilagin inhibits the reaction [Doxorubicin results in decreased activity of CAT protein]; corilagin inhibits the reaction [Methylnitronitrosoguanidine results in decreased activity of CAT protein]; corilagin inhibits the reaction [Streptozocin results in decreased activity of CAT protein] corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of CAT mRNA] |
CTD |
PMID:30582900 PMID:34605098 PMID:35103375 PMID:35307913 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
corilagin inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]; corilagin inhibits the reaction [TNFSF11 protein results in increased expression of FOS protein] |
CTD |
PMID:35307913 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO |
[corilagin co-treated with TNFSF11 protein] results in increased expression of GSR mRNA |
CTD |
PMID:35307913 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
EXP |
corilagin inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of HIF1A mRNA] |
CTD |
PMID:35103375 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
EXP |
corilagin inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of HMGB1 mRNA] |
CTD |
PMID:35103375 |
|
NCBI chr12:5,973,062...5,978,565
Ensembl chr12:5,901,586...5,978,565
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions |
EXP |
corilagin inhibits the reaction [Doxorubicin results in increased activity of HMGCR protein] |
CTD |
PMID:34605098 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of HMOX1 protein]; tin protoporphyrin IX inhibits the reaction [corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of HMOX1 protein]] |
CTD |
PMID:35307913 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
corilagin inhibits the reaction [Doxorubicin results in increased expression of IL6 protein] |
CTD |
PMID:34605098 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ldha |
lactate dehydrogenase A |
multiple interactions |
EXP |
corilagin inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of LDHA mRNA] |
CTD |
PMID:35103375 |
|
NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472
|
|
G |
Nfatc1 |
nuclear factor of activated T-cells 1 |
multiple interactions |
ISO |
corilagin inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]; corilagin inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 protein] |
CTD |
PMID:35307913 |
|
NCBI chr18:74,046,421...74,156,041
Ensembl chr18:74,046,904...74,156,028
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of NFE2L2 mRNA] |
CTD |
PMID:35307913 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
EXP |
corilagin inhibits the reaction [1-naphthyl isothiocyanate decreases expression of nr1h4 mRNA and protein in rat liver]; corilagin increases expression of nr1h4 mRNA and protein in rat embryonic liver cells |
RGD |
PMID:29235094 |
RGD:15042872 |
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Pik3cg |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma |
multiple interactions |
EXP |
corilagin inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of PIK3CG mRNA] |
CTD |
PMID:35103375 |
|
NCBI chr 6:48,766,778...48,802,098
Ensembl chr 6:48,766,864...48,802,043
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
EXP |
corilagin inhibits the reaction [Doxorubicin results in increased expression of PPARG protein] |
CTD |
PMID:34605098 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Slc16a3 |
solute carrier family 16 member 3 |
multiple interactions |
EXP |
corilagin inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of SLC16A3 mRNA] |
CTD |
PMID:35103375 |
|
NCBI chr10:106,212,679...106,222,564
Ensembl chr10:106,212,778...106,222,562
|
|
G |
Tnf |
tumor necrosis factor |
decreases secretion multiple interactions |
ISO EXP |
corilagin results in decreased secretion of TNF protein corilagin inhibits the reaction [Doxorubicin results in increased expression of TNF protein] |
CTD |
PMID:12628509 PMID:34605098 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions |
ISO |
[corilagin co-treated with TNFSF11 protein] results in increased expression of GSR mRNA; corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of CAT mRNA]; corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of HMOX1 protein]; corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of NFE2L2 mRNA]; corilagin inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]; corilagin inhibits the reaction [TNFSF11 protein results in increased expression of FOS protein]; corilagin inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]; corilagin inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 protein]; tin protoporphyrin IX inhibits the reaction [corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of HMOX1 protein]] |
CTD |
PMID:35307913 |
|
NCBI chr15:53,674,990...53,705,171
Ensembl chr15:53,673,877...53,705,445
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases expression increases phosphorylation decreases phosphorylation multiple interactions |
ISO EXP |
dactolisib results in decreased expression of AKT1 protein modified form dactolisib increases phosphorylation of Akt in rat tumor grafts dactolisib results in decreased phosphorylation of AKT1 protein dactolisib inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]; LEPR affects the reaction [dactolisib results in decreased phosphorylation of AKT1 protein] dactolisib inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; mirdametinib promotes the reaction [dactolisib results in decreased phosphorylation of AKT1 protein] |
CTD RGD |
PMID:19435893 PMID:21464613 PMID:22415236 PMID:22949526 PMID:23151917 PMID:24758408 PMID:25640480 PMID:26983879 More...
|
RGD:152177690 |
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
Chloroquine promotes the reaction [dactolisib affects the folding of and results in increased activity of BAX protein]; dactolisib affects the folding of and results in increased activity of BAX protein; dactolisib promotes the reaction [Chloroquine affects the folding of and results in increased activity of BAX protein] |
CTD |
PMID:23151917 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
affects expression |
ISO |
dactolisib affects the expression of BCL2L1 protein |
CTD |
PMID:25640480 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
affects expression |
ISO |
dactolisib affects the expression of BCL2L11 protein |
CTD |
PMID:25640480 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
ISO |
dactolisib results in decreased expression of BIRC5 protein |
CTD |
PMID:22729845 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions increases cleavage |
ISO |
dactolisib results in increased activity of CASP3 protein Chloroquine promotes the reaction [dactolisib results in increased cleavage of CASP3 protein]; dactolisib promotes the reaction [Chloroquine results in increased cleavage of CASP3 protein] |
CTD |
PMID:21372221 PMID:23151917 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases cleavage |
ISO |
Chloroquine promotes the reaction [dactolisib results in increased cleavage of CASP9 protein]; dactolisib promotes the reaction [Chloroquine results in increased cleavage of CASP9 protein] |
CTD |
PMID:23151917 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccnd1 |
cyclin D1 |
decreases phosphorylation |
ISO |
dactolisib results in decreased phosphorylation of CCND1 protein |
CTD |
PMID:23651616 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
dactolisib results in increased expression of CDKN1A protein |
CTD |
PMID:23651616 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Ctsb |
cathepsin B |
affects localization multiple interactions |
ISO |
dactolisib affects the localization of CTSB protein [Chloroquine co-treated with dactolisib] affects the localization of CTSB protein |
CTD |
PMID:23151917 |
|
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
dactolisib inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:24758408 |
|
NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
decreases phosphorylation multiple interactions increases response to substance |
ISO |
dactolisib results in decreased phosphorylation of EIF4EBP1 protein Ku 0063794 inhibits the reaction [dactolisib results in decreased phosphorylation of EIF4EBP1 protein]; mirdametinib promotes the reaction [dactolisib results in decreased phosphorylation of EIF4EBP1 protein] EIF4EBP1 protein modified form results in increased susceptibility to dactolisib |
CTD |
PMID:21372221 PMID:22415236 PMID:23151917 PMID:25640480 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
decreases activity |
ISO |
dactolisib results in decreased activity of HSF1 protein |
CTD |
PMID:34170685 |
|
NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
|
|
G |
Lepr |
leptin receptor |
multiple interactions |
ISO |
LEPR affects the reaction [dactolisib results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:22949526 |
|
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Map1lc3a |
microtubule-associated protein 1 light chain 3 alpha |
increases metabolic processing affects localization |
ISO |
dactolisib results in increased metabolism of MAP1LC3A protein dactolisib affects the localization of MAP1LC3A protein |
CTD |
PMID:23651616 |
|
NCBI chr 3:143,783,024...143,784,670
Ensembl chr 3:143,783,024...143,784,670
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
dactolisib promotes the reaction [mirdametinib results in decreased phosphorylation of MAPK1 protein] |
CTD |
PMID:22415236 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
dactolisib promotes the reaction [mirdametinib results in decreased phosphorylation of MAPK3 protein] |
CTD |
PMID:22415236 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
affects expression multiple interactions |
ISO |
dactolisib affects the expression of MCL1 protein [dactolisib co-treated with (+)-JQ1 compound] affects the expression of MCL1 protein |
CTD |
PMID:25640480 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Ogt |
O-linked N-acetylglucosamine (GlcNAc) transferase |
increases response to substance |
ISO |
OGT mutant form results in increased susceptibility to dactolisib |
CTD |
PMID:23029544 |
|
NCBI chr X:66,771,278...66,816,148
Ensembl chr X:66,771,349...66,816,146
|
|
G |
Oxsr1 |
oxidative stress responsive kinase 1 |
multiple interactions decreases phosphorylation |
ISO |
dactolisib inhibits the reaction [INS1 protein results in increased phosphorylation of OXSR1 protein] dactolisib results in decreased phosphorylation of OXSR1 protein |
CTD |
PMID:22949526 |
|
NCBI chr 8:118,972,754...119,062,102
Ensembl chr 8:118,972,754...119,062,027
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
dactolisib results in increased cleavage of PARP1 protein |
CTD |
PMID:21464613 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha |
increases response to substance decreases response to substance |
ISO |
PIK3CA results in increased susceptibility to dactolisib PIK3CA results in decreased susceptibility to dactolisib |
CTD |
PMID:21372221 PMID:21633166 |
|
NCBI chr 2:115,175,275...115,249,034
Ensembl chr 2:115,174,984...115,249,032
|
|
G |
Pten |
phosphatase and tensin homolog |
increases response to substance |
ISO |
PTEN gene mutant form results in increased susceptibility to dactolisib |
CTD |
PMID:21372221 |
|
NCBI chr 1:230,631,303...230,696,754
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases expression |
ISO |
dactolisib results in decreased expression of RB1 protein modified form |
CTD |
PMID:23651616 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rps6 |
ribosomal protein S6 |
multiple interactions decreases phosphorylation |
ISO |
mirdametinib promotes the reaction [dactolisib results in decreased phosphorylation of RPS6 protein] |
CTD |
PMID:21372221 PMID:21464613 PMID:21498705 PMID:22415236 PMID:23151917 PMID:25640480 More...
|
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
decreases phosphorylation |
ISO |
dactolisib results in decreased phosphorylation of RPS6KB1 protein |
CTD |
PMID:21464613 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Slc12a3 |
solute carrier family 12 member 3 |
multiple interactions decreases phosphorylation |
ISO |
dactolisib inhibits the reaction [INS1 protein results in increased phosphorylation of SLC12A3 protein] dactolisib results in decreased phosphorylation of SLC12A3 protein |
CTD |
PMID:22949526 |
|
NCBI chr19:10,630,649...10,679,250
Ensembl chr19:10,631,393...10,669,091
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions decreases expression |
ISO |
bafilomycin A1 inhibits the reaction [dactolisib results in decreased expression of SQSTM1 protein]; Chloroquine inhibits the reaction [dactolisib results in decreased expression of SQSTM1 protein] |
CTD |
PMID:23151917 PMID:23651616 |
|
NCBI chr10:34,525,517...34,536,685
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Stk39 |
serine threonine kinase 39 |
multiple interactions decreases phosphorylation |
ISO |
dactolisib inhibits the reaction [INS1 protein results in increased phosphorylation of STK39 protein] dactolisib results in decreased phosphorylation of STK39 protein |
CTD |
PMID:22949526 |
|
NCBI chr 3:52,913,583...53,179,060
Ensembl chr 3:52,913,585...53,179,060
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases activity multiple interactions |
ISO |
Dehydroepiandrosterone Sulfate results in decreased activity of ABCB11 protein Dehydroepiandrosterone Sulfate inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] |
CTD |
PMID:24014644 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
increases expression multiple interactions |
ISO |
Dehydroepiandrosterone Sulfate results in increased expression of ACOX1 mRNA PPARA protein affects the reaction [Dehydroepiandrosterone Sulfate results in increased expression of ACOX1 mRNA] |
CTD |
PMID:8700121 |
|
NCBI chr10:101,406,197...101,431,242
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression multiple interactions |
EXP |
Dehydroepiandrosterone Sulfate results in increased expression of BCL2 protein Pertussis Toxin inhibits the reaction [Dehydroepiandrosterone Sulfate results in increased expression of BCL2 protein] |
CTD |
PMID:16407456 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
increases expression multiple interactions |
EXP |
Dehydroepiandrosterone Sulfate results in increased expression of BCL2L1 protein Pertussis Toxin inhibits the reaction [Dehydroepiandrosterone Sulfate results in increased expression of BCL2L1 protein] |
CTD |
PMID:16407456 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions increases expression |
EXP |
[Dehydroepiandrosterone Sulfate co-treated with Phenobarbital] results in increased expression of CPT1A protein Dehydroepiandrosterone Sulfate results in increased expression of CPT1A protein |
CTD |
PMID:25786523 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
multiple interactions |
EXP |
[Dehydroepiandrosterone Sulfate co-treated with Phenobarbital] results in increased expression of CYP2C11 protein |
CTD |
PMID:25786523 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
multiple interactions |
EXP |
[Dehydroepiandrosterone Sulfate co-treated with Phenobarbital] results in increased expression of CYP2C6V1 protein |
CTD |
PMID:25786523 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions affects metabolic processing |
EXP ISO |
[Dehydroepiandrosterone Sulfate co-treated with Phenobarbital] results in increased expression of CYP3A2 protein CYP3A4 protein affects the metabolism of Dehydroepiandrosterone Sulfate |
CTD |
PMID:2271712 PMID:25786523 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp4a1 |
cytochrome P450, family 4, subfamily a, polypeptide 1 |
increases expression multiple interactions |
EXP |
Dehydroepiandrosterone Sulfate results in increased expression of CYP4A1 mRNA; Dehydroepiandrosterone Sulfate results in increased expression of CYP4A1 protein [Dehydroepiandrosterone Sulfate co-treated with Phenobarbital] results in increased expression of CYP4A1 protein |
CTD |
PMID:8700121 PMID:25786523 |
|
NCBI chr 5:129,123,323...129,137,464
Ensembl chr 5:129,123,336...129,137,464
|
|
G |
Cyp4a3 |
cytochrome P450, family 4, subfamily a, polypeptide 3 |
increases expression |
EXP |
Dehydroepiandrosterone Sulfate results in increased expression of CYP4A3 mRNA |
CTD |
PMID:8700121 |
|
NCBI chr 5:129,097,571...129,115,488
Ensembl chr 5:129,097,926...129,115,463
|
|
G |
Ehhadh |
enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase |
increases expression multiple interactions |
ISO |
Dehydroepiandrosterone Sulfate results in increased expression of EHHADH mRNA PPARA protein affects the reaction [Dehydroepiandrosterone Sulfate results in increased expression of EHHADH mRNA] |
CTD |
PMID:8700121 |
|
NCBI chr11:79,241,927...79,275,173
Ensembl chr11:79,241,938...79,275,188
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
increases expression multiple interactions |
ISO |
Dehydroepiandrosterone Sulfate results in increased expression of FABP1 mRNA PPARA protein affects the reaction [Dehydroepiandrosterone Sulfate results in increased expression of FABP1 mRNA] |
CTD |
PMID:8700121 |
|
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[Morphine co-treated with Dehydroepiandrosterone Sulfate] results in decreased expression of FOS protein |
CTD |
PMID:15196791 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases abundance |
ISO |
Dexamethasone inhibits the reaction [IL1B protein results in increased abundance of Dehydroepiandrosterone Sulfate] |
CTD |
PMID:12548226 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
[Morphine co-treated with Dehydroepiandrosterone Sulfate] results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:15196791 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Nat1 |
N-acetyltransferase 1 |
multiple interactions |
ISO |
Dehydroepiandrosterone Sulfate inhibits the reaction [NAT1 protein results in increased acetylation of 4-Aminobenzoic Acid]; Dehydroepiandrosterone Sulfate promotes the reaction [NAT1 protein results in increased acetylation of 4-Aminobenzoic Acid] |
CTD |
PMID:11470991 |
|
NCBI chr16:22,218,217...22,238,516
Ensembl chr16:22,208,194...22,238,520
|
|
G |
Pomc |
proopiomelanocortin |
increases abundance |
ISO |
POMC results in increased abundance of Dehydroepiandrosterone Sulfate |
CTD |
PMID:2161262 |
|
NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions increases response to substance |
ISO |
PPARA protein affects the reaction [Dehydroepiandrosterone Sulfate results in increased expression of ACOX1 mRNA]; PPARA protein affects the reaction [Dehydroepiandrosterone Sulfate results in increased expression of CYP4A1 mRNA]; PPARA protein affects the reaction [Dehydroepiandrosterone Sulfate results in increased expression of CYP4A3 mRNA]; PPARA protein affects the reaction [Dehydroepiandrosterone Sulfate results in increased expression of EHHADH mRNA]; PPARA protein affects the reaction [Dehydroepiandrosterone Sulfate results in increased expression of FABP1 mRNA] PPARA protein results in increased susceptibility to Dehydroepiandrosterone Sulfate |
CTD |
PMID:8700121 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Prl |
prolactin |
increases abundance |
ISO |
PRL protein results in increased abundance of Dehydroepiandrosterone Sulfate |
CTD |
PMID:2943108 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Sirt1 |
sirtuin 1 |
increases expression |
EXP |
Dehydroepiandrosterone Sulfate results in increased expression of SIRT1 protein |
CTD |
PMID:25786523 |
|
NCBI chr20:25,307,143...25,329,260
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Sirt6 |
sirtuin 6 |
increases expression |
EXP |
Dehydroepiandrosterone Sulfate results in increased expression of SIRT6 protein |
CTD |
PMID:25786523 |
|
NCBI chr 7:8,082,312...8,087,776
Ensembl chr 7:8,082,364...8,098,914
|
|
G |
Slc10a6 |
solute carrier family 10 member 6 |
increases transport |
ISO |
SLC10A6 protein results in increased transport of Dehydroepiandrosterone Sulfate |
CTD |
PMID:23562556 |
|
NCBI chr14:6,080,716...6,102,037
Ensembl chr14:6,080,717...6,103,037
|
|
G |
Slc22a12 |
solute carrier family 22 member 12 |
multiple interactions |
ISO |
Potassium promotes the reaction [SLC22A12 protein results in increased uptake of Dehydroepiandrosterone Sulfate] |
CTD |
PMID:15284287 |
|
NCBI chr 1:203,845,039...203,852,496
Ensembl chr 1:203,845,048...203,853,555
|
|
G |
Slc22a25 |
solute carrier family 22, member 25 |
increases uptake affects transport multiple interactions |
EXP ISO |
SLC22A9 protein results in increased uptake of Dehydroepiandrosterone Sulfate SLC22A19 protein affects the transport of Dehydroepiandrosterone Sulfate Dehydroepiandrosterone Sulfate inhibits the reaction [SLC22A9 protein results in increased uptake of estrone sulfate] |
CTD |
PMID:16079298 PMID:17132213 PMID:18441515 |
|
NCBI chr 1:205,338,698...205,498,486
Ensembl chr 1:205,338,699...205,433,085
|
|
G |
Slc22a7 |
solute carrier family 22 member 7 |
increases transport |
ISO |
SLC22A7 protein results in increased transport of Dehydroepiandrosterone Sulfate |
CTD |
PMID:15901346 |
|
NCBI chr 9:14,547,073...14,554,354
Ensembl chr 9:14,547,849...14,553,921
|
|
G |
Slc22a8 |
solute carrier family 22 member 8 |
affects transport increases uptake |
ISO |
SLC22A8 protein affects the transport of Dehydroepiandrosterone Sulfate SLC22A8 protein results in increased uptake of Dehydroepiandrosterone Sulfate |
CTD |
PMID:11306713 PMID:16098483 PMID:17255469 |
|
NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions |
ISO |
Dehydroepiandrosterone Sulfate inhibits the reaction [SLCO1B3 protein results in increased susceptibility to cyanoginosin LR]; Dehydroepiandrosterone Sulfate inhibits the reaction [SLCO1B3 protein results in increased susceptibility to Okadaic Acid] |
CTD |
PMID:26134461 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
increases phosphorylation |
EXP |
Dehydroepiandrosterone Sulfate results in increased phosphorylation of SRC protein |
CTD |
PMID:16407456 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Sts |
steroid sulfatase |
affects metabolic processing |
ISO |
STS protein affects the metabolism of Dehydroepiandrosterone Sulfate |
CTD |
PMID:16054388 |
|
NCBI chr X:42,225,131...42,233,403
Ensembl chr X:42,225,372...42,233,402
|
|
|
G |
Acp3 |
acid phosphatase 3 |
increases expression |
ISO |
Ellagic Acid results in increased expression of ACP3 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 8:104,905,570...104,956,146
Ensembl chr 8:104,905,586...104,954,236
|
|
G |
Acp5 |
acid phosphatase 5, tartrate resistant |
multiple interactions |
ISO |
Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 protein] |
CTD |
PMID:32971123 |
|
NCBI chr 8:20,663,984...20,670,604
Ensembl chr 8:20,663,985...20,667,929
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
increases expression |
ISO |
Ellagic Acid results in increased expression of AIFM1 protein |
CTD |
PMID:23554011 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation |
ISO |
Ellagic Acid results in increased phosphorylation of AKT1 protein |
CTD |
PMID:26986492 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
multiple interactions affects binding |
ISO |
ALB protein promotes the reaction [Ellagic Acid results in increased activity of F12 protein] Ellagic Acid binds to ALB protein |
CTD |
PMID:6343536 PMID:25247703 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Alkbh2 |
alkB homolog 2, alpha-ketoglutarate-dependent dioxygenase |
decreases activity |
ISO |
Ellagic Acid results in decreased activity of ALKBH2 protein |
CTD |
PMID:31088072 |
|
NCBI chr12:42,494,187...42,500,929
Ensembl chr12:42,496,300...42,500,914
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
decreases expression increases expression |
ISO |
Ellagic Acid results in decreased expression of APAF1 mRNA Ellagic Acid results in increased expression of APAF1 mRNA |
CTD |
PMID:12002526 PMID:35179410 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Ascl1 |
achaete-scute family bHLH transcription factor 1 |
increases expression |
ISO |
Ellagic Acid results in increased expression of ASCL1 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 7:21,904,153...21,906,003
Ensembl chr 7:21,903,126...21,905,993
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
increases expression |
ISO |
Ellagic Acid results in increased expression of ASNS mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
ISO |
Ellagic Acid results in increased expression of ATF3 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atg5 |
autophagy related 5 |
increases expression |
ISO |
Ellagic Acid results in increased expression of ATG5 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr20:47,798,222...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Bad |
BCL2-associated agonist of cell death |
increases expression |
ISO |
Ellagic Acid results in increased expression of BAD protein |
CTD |
PMID:23554011 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
EXP ISO |
Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of BAX mRNA] Ellagic Acid results in increased expression of BAX mRNA |
CTD |
PMID:29854611 PMID:35179410 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression decreases expression multiple interactions |
ISO EXP |
Ellagic Acid results in increased expression of BCL2 protein Ellagic Acid results in decreased expression of BCL2 mRNA Ellagic Acid inhibits the reaction [sodium arsenate results in decreased expression of BCL2 mRNA] [Ellagic Acid co-treated with resveratrol] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA] |
CTD |
PMID:20103723 PMID:22386815 PMID:29854611 PMID:35179410 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of BMP6 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr17:26,318,121...26,469,034
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Brf1 |
BRF1, RNA polymerase III transcription initiation factor subunit |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of BRF1 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 6:132,034,380...132,081,296
Ensembl chr 6:132,037,272...132,081,278
|
|
G |
Calr |
calreticulin |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of CALR mRNA |
CTD |
PMID:12002526 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Casp3 |
caspase 3 |
increases expression multiple interactions increases activity decreases activity decreases expression |
ISO EXP |
Ellagic Acid results in increased expression of CASP3 mRNA Ellagic Acid inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein]; Ellagic Acid inhibits the reaction [sodium arsenate results in increased activity of CASP3 protein] Ellagic Acid results in increased expression of and results in increased activity of CASP3 protein Ellagic Acid results in increased activity of CASP3 protein Ellagic Acid results in decreased activity of CASP3 protein Ellagic Acid results in decreased expression of CASP3 mRNA |
CTD |
PMID:12002526 PMID:22386815 PMID:23554011 PMID:23811531 PMID:28815802 PMID:29854611 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
Ellagic Acid results in increased expression of and results in increased activity of CASP9 protein |
CTD |
PMID:23554011 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
increases activity multiple interactions |
EXP |
Ellagic Acid results in increased activity of CAT protein Ellagic Acid inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased activity of CAT protein]; Ellagic Acid inhibits the reaction [sodium arsenite results in decreased activity of CAT protein] |
CTD |
PMID:20074268 PMID:24877639 PMID:29864931 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases secretion |
ISO |
Ellagic Acid results in decreased secretion of CCL2 protein |
CTD |
PMID:20816778 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccng1 |
cyclin G1 |
decreases expression |
EXP |
ellagic acid inhibits the reaction [estrogen increases expression of Ccng1 mRNA and protein in rat mammary tissue] |
RGD |
PMID:23791885 |
RGD:151356928 |
NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641
|
|
G |
Cd14 |
CD14 molecule |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of CD14 mRNA |
CTD |
PMID:20816778 |
|
NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of CDK1 protein |
CTD |
PMID:23554011 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
[resveratrol co-treated with Ellagic Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CDKN1A mRNA] [Ellagic Acid co-treated with Quercetin] results in increased expression of CDKN1A mRNA; Ellagic Acid promotes the reaction [Quercetin results in increased expression of CDKN1A protein]; pifithrin inhibits the reaction [Ellagic Acid promotes the reaction [Quercetin results in increased expression of CDKN1A protein]] Ellagic Acid results in increased expression of CDKN1A protein |
CTD |
PMID:15735102 PMID:20103723 PMID:23554011 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Ctsd |
cathepsin D |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [Isoproterenol results in increased activity of CTSD protein] |
CTD |
PMID:21762681 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Ctsk |
cathepsin K |
multiple interactions |
ISO |
Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of CTSK mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of CTSK protein] |
CTD |
PMID:32971123 |
|
NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases expression decreases activity |
ISO |
Ellagic Acid results in decreased expression of CYP1A1 mRNA Ellagic Acid results in decreased activity of CYP1A1 protein |
CTD |
PMID:19329757 PMID:20816778 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity multiple interactions |
ISO |
Ellagic Acid results in decreased activity of CYP1B1 protein [Ellagic Acid co-treated with Plant Extracts] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1B1 mRNA]; [Ellagic Acid co-treated with resveratrol] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1B1 mRNA] |
CTD |
PMID:19329757 PMID:20103723 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Daxx |
death-domain associated protein |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of DAXX mRNA |
CTD |
PMID:12002526 |
|
NCBI chr20:4,970,090...4,976,145
Ensembl chr20:4,970,092...4,975,843
|
|
G |
Dffa |
DNA fragmentation factor subunit alpha |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of DFFA mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 5:159,540,718...159,553,639
Ensembl chr 5:159,540,715...159,553,633
|
|
G |
E4f1 |
E4F transcription factor 1 |
increases expression |
ISO |
Ellagic Acid results in increased expression of E4F1 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr10:13,471,478...13,495,018
Ensembl chr10:13,474,456...13,485,974
|
|
G |
Egr3 |
early growth response 3 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of EGR3 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr15:45,150,335...45,156,052
Ensembl chr15:45,150,567...45,154,627
|
|
G |
Endog |
endonuclease G |
increases expression |
ISO |
Ellagic Acid results in increased expression of ENDOG protein |
CTD |
PMID:23554011 |
|
NCBI chr 3:13,449,113...13,451,715
Ensembl chr 3:13,449,086...13,451,932
|
|
G |
Ep300 |
E1A binding protein p300 |
increases expression |
ISO |
Ellagic Acid results in increased expression of EP300 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Eps15 |
epidermal growth factor receptor pathway substrate 15 |
increases expression |
ISO |
Ellagic Acid results in increased expression of EPS15 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 5:124,045,865...124,146,221
Ensembl chr 5:124,045,926...124,146,221
|
|
G |
Ezh1 |
enhancer of zeste 1 polycomb repressive complex 2 subunit |
increases expression |
ISO |
Ellagic Acid results in increased expression of EZH1 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr10:86,126,023...86,162,001
Ensembl chr10:86,126,015...86,161,921
|
|
G |
F12 |
coagulation factor XII |
multiple interactions increases activity |
ISO |
ALB protein promotes the reaction [Ellagic Acid results in increased activity of F12 protein] |
CTD |
PMID:6343536 |
|
NCBI chr17:9,207,683...9,215,530
Ensembl chr17:9,207,683...9,215,530
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of FGFR1 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr16:66,492,445...66,546,731
Ensembl chr16:66,494,042...66,547,350
|
|
G |
Flna |
filamin A |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of FLNA mRNA |
CTD |
PMID:12002526 |
|
NCBI chr X:152,007,758...152,034,266
Ensembl chr X:152,007,758...152,031,052
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of FN1 protein] |
CTD |
PMID:24877639 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[Ellagic Acid co-treated with Plant Extracts] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of FOS mRNA]; [Ellagic Acid co-treated with Resveratrol] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of FOS mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of FOS protein] |
CTD |
PMID:20103723 PMID:32971123 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
decreases activity |
ISO |
Ellagic Acid results in decreased activity of G6PD protein |
CTD |
PMID:25130191 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gal |
galanin and GMAP prepropeptide |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [phosalone results in increased activity of GAL protein] |
CTD |
PMID:27965107 |
|
NCBI chr 1:200,650,439...200,655,302
Ensembl chr 1:200,650,439...200,654,959
|
|
G |
Gpld1 |
glycosylphosphatidylinositol specific phospholipase D1 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of GPLD1 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr17:40,084,427...40,132,035
Ensembl chr17:40,084,617...40,126,939
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of GPT protein]; Ellagic Acid inhibits the reaction [sodium arsenite results in increased expression of GPT protein] |
CTD |
PMID:24877639 PMID:29935397 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [sodium arsenite results in decreased expression of GPX1 mRNA] |
CTD |
PMID:29935397 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased activity of GSR protein] |
CTD |
PMID:24877639 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gsta4 |
glutathione S-transferase alpha 4 |
increases expression |
ISO |
Ellagic Acid results in increased expression of GSTA4 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182
|
|
G |
Gstt1 |
glutathione S-transferase theta 1 |
affects expression |
EXP |
Ellagic Acid affects the expression of GSTT1 protein |
CTD |
PMID:9855024 |
|
NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585
|
|
G |
Gtf2e2 |
general transcription factor IIE subunit 2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of GTF2E2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr16:58,399,307...58,449,467
Ensembl chr16:58,399,107...58,449,371
|
|
G |
Gtf2h4 |
general transcription factor 2H subunit 4 |
increases expression |
ISO |
Ellagic Acid results in increased expression of GTF2H4 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr20:3,071,328...3,076,990
Ensembl chr20:3,071,328...3,076,984
|
|
G |
Gusb |
glucuronidase, beta |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [Isoproterenol results in increased activity of GUSB protein] |
CTD |
PMID:21762681 |
|
NCBI chr12:26,701,191...26,714,718
Ensembl chr12:26,697,951...26,726,905
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of HIF1A mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hlcs |
holocarboxylase synthetase |
decreases activity |
ISO |
Ellagic Acid results in decreased activity of HLCS protein |
CTD |
PMID:26303405 |
|
NCBI chr11:33,455,806...33,635,197
Ensembl chr11:33,455,809...33,624,222
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO |
Ellagic Acid results in increased expression of HMOX1 mRNA; Ellagic Acid results in increased expression of HMOX1 protein [Paraquat co-treated with Ellagic Acid] results in increased expression of HMOX1 mRNA; [Paraquat co-treated with Ellagic Acid] results in increased expression of HMOX1 protein |
CTD |
PMID:22386815 PMID:23546295 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
multiple interactions |
ISO |
[Ellagic Acid co-treated with Plant Extracts] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased mutagenesis of HRAS gene]; [Ellagic Acid co-treated with resveratrol] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased mutagenesis of HRAS gene] |
CTD |
PMID:20103723 |
|
NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Ier2 |
immediate early response 2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of IER2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr19:23,494,551...23,496,075
Ensembl chr19:23,494,184...23,499,211
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of IFNG mRNA]; Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of IFNG protein] |
CTD |
PMID:29854611 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igfbp2 |
insulin-like growth factor binding protein 2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of IGFBP2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 9:74,415,574...74,442,945
Ensembl chr 9:74,415,546...74,442,937
|
|
G |
Igfbp4 |
insulin-like growth factor binding protein 4 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of IGFBP4 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr10:83,995,253...84,007,272
Ensembl chr10:83,989,591...84,007,225
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression multiple interactions |
ISO EXP |
Ellagic Acid results in decreased expression of IL1B mRNA Ellagic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of IL1B protein]; Ellagic Acid inhibits the reaction [Glucose results in increased expression of IL1B protein]; Ellagic Acid inhibits the reaction [Isoproterenol results in increased expression of IL1B mRNA]; Ellagic Acid inhibits the reaction [phosalone results in increased expression of IL1B protein]; Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of IL1B mRNA]; Ellagic Acid inhibits the reaction [sodium arsenite results in increased expression of IL1B protein] Ellagic Acid inhibits the reaction [IL1B protein results in increased secretion of CXCL8 protein] |
CTD |
PMID:18377686 PMID:20816778 PMID:21762681 PMID:24877639 PMID:27965107 PMID:29455002 PMID:29854611 PMID:29864931 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1r1 |
interleukin 1 receptor type 1 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of IL1R1 mRNA |
CTD |
PMID:20816778 |
|
NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of IL6 protein]; Ellagic Acid inhibits the reaction [Glucose results in increased expression of IL6 protein]; Ellagic Acid inhibits the reaction [Isoproterenol results in increased expression of IL6 mRNA]; Ellagic Acid inhibits the reaction [phosalone results in increased expression of IL6 protein] |
CTD |
PMID:21762681 PMID:24877639 PMID:27965107 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inpp5d |
inositol polyphosphate-5-phosphatase D |
increases expression |
ISO |
Ellagic Acid results in increased expression of INPP5D mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 9:88,287,680...88,392,748
Ensembl chr 9:88,287,677...88,392,746
|
|
G |
Iqgap2 |
IQ motif containing GTPase activating protein 2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of IQGAP2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 2:26,894,836...27,170,270
Ensembl chr 2:26,894,825...27,170,279
|
|
G |
Irf9 |
interferon regulatory factor 9 |
increases expression |
ISO |
Ellagic Acid results in increased expression of IRF9 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr15:29,095,474...29,101,924
Ensembl chr15:29,095,789...29,101,236
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of JUN mRNA; Ellagic Acid results in decreased expression of JUN protein modified form |
CTD |
PMID:23811531 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Litaf |
lipopolysaccharide-induced TNF factor |
increases expression |
ISO |
Ellagic Acid results in increased expression of LITAF mRNA |
CTD |
PMID:12002526 |
|
NCBI chr10:4,656,308...4,692,981
Ensembl chr10:4,625,552...4,692,763
|
|
G |
Map1a |
microtubule-associated protein 1A |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of MAP1A mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 3:108,263,217...108,283,936
Ensembl chr 3:108,263,151...108,282,899
|
|
G |
Map3k1 |
mitogen-activated protein kinase kinase kinase 1 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of MAP3K1 mRNA; Ellagic Acid results in decreased expression of MAP3K1 protein |
CTD |
PMID:23811531 |
|
NCBI chr 2:43,348,572...43,414,706
Ensembl chr 2:43,350,098...43,414,463
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:32971123 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk11 |
mitogen-activated protein kinase 11 |
increases expression |
ISO |
Ellagic Acid results in increased expression of MAPK11 mRNA |
CTD |
PMID:23811531 |
|
NCBI chr 7:120,218,471...120,225,488
Ensembl chr 7:120,218,478...120,225,395
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [phosalone results in increased expression of MAPK14 protein] |
CTD |
PMID:27965107 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:32971123 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
[Ellagic Acid co-treated with Quercetin] results in increased phosphorylation of MAPK8 protein |
CTD |
PMID:15735102 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
ISO |
[Ellagic Acid co-treated with Quercetin] results in increased phosphorylation of MAPK9 protein |
CTD |
PMID:15735102 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
decreases activity |
EXP |
Ellagic Acid results in decreased activity of MGST1 protein |
CTD |
PMID:16125204 |
|
NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892
|
|
G |
Mmd |
monocyte to macrophage differentiation-associated |
increases expression |
ISO |
Ellagic Acid results in increased expression of MMD mRNA |
CTD |
PMID:12002526 |
|
NCBI chr10:75,073,278...75,101,528
Ensembl chr10:75,073,365...75,101,528
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions decreases expression decreases activity |
ISO |
Ellagic Acid results in decreased activity of and results in decreased secretion of MMP2 protein; zinc chloride inhibits the reaction [Ellagic Acid results in decreased activity of and results in decreased secretion of MMP2 protein] Ellagic Acid results in decreased expression of MMP2 mRNA Ellagic Acid results in decreased activity of MMP2 protein |
CTD |
PMID:21573219 PMID:35179410 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases expression decreases activity |
ISO |
Ellagic Acid results in decreased expression of MMP9 mRNA Ellagic Acid results in decreased activity of MMP9 protein |
CTD |
PMID:35179410 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Nfatc1 |
nuclear factor of activated T-cells 1 |
multiple interactions |
ISO |
Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 protein] |
CTD |
PMID:32971123 |
|
NCBI chr18:74,046,421...74,156,041
Ensembl chr18:74,046,904...74,156,028
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
affects localization increases expression multiple interactions affects response to substance |
ISO |
Ellagic Acid affects the localization of NFE2L2 protein Ellagic Acid results in increased expression of NFE2L2 mRNA Ellagic Acid inhibits the reaction [sodium arsenate results in decreased expression of NFE2L2 mRNA] [Paraquat co-treated with Ellagic Acid] results in increased expression of and affects the localization of NFE2L2 protein; [Paraquat co-treated with Ellagic Acid] results in increased expression of NFE2L2 mRNA; Ellagic Acid results in increased expression of and affects the localization of NFE2L2 protein Ellagic Acid results in increased expression of NFE2L2 mRNA; Ellagic Acid results in increased expression of NFE2L2 protein NFE2L2 protein affects the susceptibility to Ellagic Acid |
CTD |
PMID:22386815 PMID:23546295 PMID:30503583 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb2 |
nuclear factor kappa B subunit 2 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of NFKB2 mRNA |
CTD |
PMID:12002526 PMID:35179410 |
|
NCBI chr 1:245,164,586...245,173,225
Ensembl chr 1:245,165,950...245,173,213
|
|
G |
Nnat |
neuronatin |
increases expression |
ISO |
Ellagic Acid results in increased expression of NNAT mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 3:146,225,941...146,228,868
Ensembl chr 3:146,226,407...146,228,834
|
|
G |
Nop56 |
NOP56 ribonucleoprotein |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of NOP56 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 3:117,476,963...117,481,847
Ensembl chr 3:117,477,053...117,481,841
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions decreases expression |
EXP ISO |
Ellagic Acid inhibits the reaction [Doxorubicin results in increased expression of NOS2 protein] Ellagic Acid results in decreased expression of NOS2 mRNA |
CTD |
PMID:28815802 PMID:35179410 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Npas2 |
neuronal PAS domain protein 2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of NPAS2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 9:41,463,361...41,642,322
Ensembl chr 9:41,463,830...41,642,320
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression multiple interactions |
ISO |
Ellagic Acid results in increased expression of NQO1 mRNA; Ellagic Acid results in increased expression of NQO1 protein [Paraquat co-treated with Ellagic Acid] results in increased expression of NQO1 mRNA; [Paraquat co-treated with Ellagic Acid] results in increased expression of NQO1 protein |
CTD |
PMID:23546295 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
increases activity |
ISO |
Ellagic Acid results in increased activity of NR1I3 protein |
CTD |
PMID:21821919 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Parg |
poly (ADP-ribose) glycohydrolase |
decreases activity |
ISO |
Ellagic Acid results in decreased activity of PARG protein |
CTD |
PMID:19840838 |
|
NCBI chr16:7,436,429...7,544,276
Ensembl chr16:7,436,476...7,544,273
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [Rotenone results in increased cleavage of PARP1 protein] |
CTD |
PMID:25247703 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
ISO |
[resveratrol co-treated with Ellagic Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of PCNA mRNA] |
CTD |
PMID:20103723 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pdia2 |
protein disulfide isomerase family A, member 2 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [Rotenone results in increased nitrosation of and results in decreased activity of PDIA2 protein] |
CTD |
PMID:25247703 |
|
NCBI chr10:15,215,824...15,218,937
Ensembl chr10:15,215,824...15,220,931
|
|
G |
Pgd |
phosphogluconate dehydrogenase |
decreases activity |
ISO |
Ellagic Acid results in decreased activity of PGD protein |
CTD |
PMID:25130191 |
|
NCBI chr 5:159,582,746...159,598,945
Ensembl chr 5:159,561,271...159,742,778
|
|
G |
Pla2g2a |
phospholipase A2 group IIA |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of PLA2G2A mRNA |
CTD |
PMID:20816778 |
|
NCBI chr 5:151,076,442...151,079,019
Ensembl chr 5:151,076,442...151,079,014
|
|
G |
Plp2 |
proteolipid protein 2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of PLP2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr X:14,834,249...14,837,648
Ensembl chr X:14,834,231...14,838,514
|
|
G |
Pml |
PML nuclear body scaffold |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of PML mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 8:58,627,347...58,661,927
Ensembl chr 8:58,628,837...58,658,971
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of PPARD mRNA |
CTD |
PMID:12002526 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression |
ISO |
Ellagic Acid results in increased expression of PPARG protein |
CTD |
PMID:23811531 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions decreases expression |
ISO |
Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of PPARGC1A mRNA] Ellagic Acid results in decreased expression of PPARGC1A mRNA |
CTD |
PMID:30503583 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Prkg1 |
protein kinase cGMP-dependent 1 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of PRKG1 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 1:228,409,883...229,638,794
Ensembl chr 1:228,408,947...229,639,080
|
|
G |
Ptn |
pleiotrophin |
decreases expression increases expression |
ISO |
Ellagic Acid results in decreased expression of PTN mRNA Ellagic Acid results in increased expression of PTN mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 4:65,293,731...65,375,572
Ensembl chr 4:65,293,734...65,375,456
|
|
G |
Ptprn2 |
protein tyrosine phosphatase, receptor type N2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of PTPRN2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 6:137,439,572...138,191,575
Ensembl chr 6:137,439,540...138,191,575
|
|
G |
Ran |
RAN, member RAS oncogene family |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of RAN mRNA |
CTD |
PMID:12002526 |
|
NCBI chr12:27,674,049...27,678,598
Ensembl chr12:27,674,050...27,678,276
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [phosalone results in increased expression of RB1 mRNA]; Ellagic Acid inhibits the reaction [phosalone results in increased expression of RB1 protein] |
CTD |
PMID:27965107 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Reck |
reversion-inducing-cysteine-rich protein with kazal motifs |
increases expression multiple interactions |
ISO |
Ellagic Acid results in increased expression of RECK mRNA; Ellagic Acid results in increased expression of RECK protein zinc chloride inhibits the reaction [Ellagic Acid results in increased expression of RECK mRNA]; zinc chloride inhibits the reaction [Ellagic Acid results in increased expression of RECK protein] |
CTD |
PMID:21573219 |
|
NCBI chr 5:58,102,915...58,169,513
Ensembl chr 5:58,102,981...58,169,502
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
decreases expression multiple interactions |
ISO EXP |
Ellagic Acid results in decreased expression of RELA mRNA Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased phosphorylation of RELA protein] Ellagic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of RELA protein]; Ellagic Acid inhibits the reaction [Glucose results in increased expression of RELA protein]; Ellagic Acid inhibits the reaction [phosalone results in increased expression of RELA protein] |
CTD |
PMID:12002526 PMID:24877639 PMID:27965107 PMID:32971123 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rgs5 |
regulator of G-protein signaling 5 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of RGS5 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr13:81,848,254...81,885,053
Ensembl chr13:81,836,304...81,885,518
|
|
G |
Scd |
stearoyl-CoA desaturase |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of SCD mRNA |
CTD |
PMID:20816778 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Septin2 |
septin 2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of SEPTIN2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 9:94,018,141...94,051,386
Ensembl chr 9:94,018,208...94,051,386
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [sodium arsenite results in decreased expression of SOD2 mRNA] |
CTD |
PMID:29935397 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sod3 |
superoxide dismutase 3 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of SOD3 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr14:58,610,104...58,615,845
Ensembl chr14:58,609,958...58,615,990
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
ISO |
Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of SRC mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of SRC protein] |
CTD |
PMID:32971123 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Star |
steroidogenic acute regulatory protein |
increases expression multiple interactions |
ISO |
Ellagic Acid results in increased expression of STAR mRNA Ellagic Acid inhibits the reaction [sodium arsenate results in decreased expression of STAR mRNA] |
CTD |
PMID:30503583 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
increases expression decreases expression |
ISO |
Ellagic Acid results in increased expression of STAT3 mRNA Ellagic Acid results in decreased expression of STAT3 mRNA |
CTD |
PMID:12002526 PMID:20816778 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Taf1c |
TATA-box binding protein associated factor, RNA polymerase 1 subunit C |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of TAF1C mRNA |
CTD |
PMID:12002526 |
|
NCBI chr19:47,652,451...47,658,971
Ensembl chr19:47,652,452...47,658,971
|
|
G |
Tcf12 |
transcription factor 12 |
increases expression |
ISO |
Ellagic Acid results in increased expression of TCF12 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 8:72,490,447...72,799,265
Ensembl chr 8:72,492,567...72,799,201
|
|
G |
Tert |
telomerase reverse transcriptase |
multiple interactions increases expression |
ISO EXP |
Ellagic Acid inhibits the reaction [Estradiol results in increased expression of TERT mRNA alternative form] Ellagic Acid inhibits the reaction [phosalone results in decreased activity of TERT protein] Ellagic Acid results in increased expression of TERT mRNA alternative form |
CTD |
PMID:19501078 PMID:27965107 |
|
NCBI chr 1:29,637,213...29,659,509
Ensembl chr 1:29,637,506...29,659,561
|
|
G |
Tfam |
transcription factor A, mitochondrial |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of TFAM mRNA |
CTD |
PMID:12002526 |
|
NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression multiple interactions |
ISO EXP |
Ellagic Acid results in increased expression of TGFB1 mRNA Ellagic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of TGFB1 protein] |
CTD |
PMID:12002526 PMID:24877639 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression |
EXP ISO |
Ellagic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of TNF protein]; Ellagic Acid inhibits the reaction [Doxorubicin results in increased expression of TNF protein]; Ellagic Acid inhibits the reaction [Glucose results in increased expression of TNF protein]; Ellagic Acid inhibits the reaction [Isoproterenol results in increased expression of TNF mRNA]; Ellagic Acid inhibits the reaction [phosalone results in increased expression of TNF protein]; Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of TNF mRNA]; Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of TNF protein]; Ellagic Acid inhibits the reaction [sodium arsenite results in increased expression of TNF protein] Ellagic Acid results in decreased expression of TNF mRNA |
CTD |
PMID:21762681 PMID:24877639 PMID:27965107 PMID:28815802 PMID:29455002 PMID:29854611 PMID:29864931 PMID:35179410 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf11a |
TNF receptor superfamily member 11A |
multiple interactions affects binding |
ISO |
Ellagic Acid inhibits the reaction [TNFSF11 protein binds to TNFRSF11A protein] Ellagic Acid binds to TNFRSF11A protein |
CTD |
PMID:32971123 |
|
NCBI chr13:21,928,370...21,986,719
Ensembl chr13:21,928,408...21,986,695
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions affects binding |
ISO |
Ellagic Acid inhibits the reaction [TNFSF11 protein binds to TNFRSF11A protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of CTSK mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of CTSK protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of FOS protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of SRC mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of SRC protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased phosphorylation of MAPK1 protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased phosphorylation of MAPK3 protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased phosphorylation of RELA protein] Ellagic Acid binds to TNFSF11 protein |
CTD |
PMID:32971123 |
|
NCBI chr15:53,674,990...53,705,171
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Tnnt2 |
troponin T2, cardiac type |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [Isoproterenol results in increased expression of TNNT2 protein] |
CTD |
PMID:21762681 |
|
NCBI chr13:47,267,325...47,285,390
Ensembl chr13:47,267,204...47,285,388
|
|
G |
Tp53 |
tumor protein p53 |
increases expression multiple interactions |
ISO EXP |
Ellagic Acid results in increased expression of TP53 mRNA; Ellagic Acid results in increased expression of TP53 protein Ellagic Acid promotes the reaction [Quercetin results in increased phosphorylation of TP53 protein]; pifithrin inhibits the reaction [Ellagic Acid promotes the reaction [Quercetin results in increased phosphorylation of TP53 protein]] Ellagic Acid inhibits the reaction [phosalone results in increased expression of TP53 mRNA]; Ellagic Acid inhibits the reaction [phosalone results in increased expression of TP53 protein] |
CTD |
PMID:15735102 PMID:23554011 PMID:27965107 PMID:35179410 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Ugp2 |
UDP-glucose pyrophosphorylase 2 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of UGP2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr14:95,456,330...95,497,483
Ensembl chr14:95,456,330...95,496,830
|
|
G |
Usp4 |
ubiquitin specific peptidase 4 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of USP4 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 8:109,035,402...109,080,427
Ensembl chr 8:109,036,099...109,080,427
|
|
G |
Wars1 |
tryptophanyl-tRNA synthetase 1 |
increases expression |
ISO |
Ellagic Acid results in increased expression of WARS1 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 6:127,776,088...127,807,273
Ensembl chr 6:127,776,090...127,807,269
|
|
G |
Wee1 |
WEE1 G2 checkpoint kinase |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of WEE1 protein |
CTD |
PMID:23554011 |
|
NCBI chr 1:164,173,681...164,197,688
Ensembl chr 1:164,174,779...164,197,688
|
|
G |
Zbtb16 |
zinc finger and BTB domain containing 16 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of ZBTB16 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 8:48,989,376...49,177,011
Ensembl chr 8:48,994,566...49,177,011
|
|
G |
Zmym2 |
zinc finger MYM-type containing 2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of ZMYM2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr15:31,035,783...31,108,945
Ensembl chr15:31,035,838...31,109,357
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases activity multiple interactions |
EXP ISO |
Fusidic Acid results in decreased activity of ABCB11 protein Fusidic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] |
CTD |
PMID:12106615 PMID:20829430 PMID:23956101 PMID:24014644 PMID:27676153 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
Fusidic Acid inhibits the reaction [ABCB1 protein results in increased export of Digoxin] |
CTD |
PMID:26888941 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
EXP |
Fusidic Acid results in decreased expression of and results in decreased activity of ABCC2 protein |
CTD |
PMID:12106615 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
Fusidic Acid inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam] |
CTD |
PMID:26888941 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
multiple interactions |
ISO |
Fusidic Acid inhibits the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid] |
CTD |
PMID:27676153 |
|
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
multiple interactions |
EXP |
Fusidic Acid inhibits the reaction [SLCO1A4 protein results in increased uptake of Rosuvastatin Calcium] |
CTD |
PMID:26888941 |
|
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions decreases activity |
EXP ISO |
Fusidic Acid inhibits the reaction [SLCO1B2 protein results in increased uptake of Rosuvastatin Calcium] Fusidic Acid inhibits the reaction [SLCO1B3 protein results in increased uptake of Rosuvastatin Calcium] Fusidic Acid results in decreased activity of SLCO1B3 protein |
CTD |
PMID:26888941 PMID:27676153 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
multiple interactions |
ISO |
Fusidic Acid inhibits the reaction [UGT1A1 protein results in increased glucuronidation of Estradiol] |
CTD |
PMID:27676153 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
|
G |
Eef1a1 |
eukaryotic translation elongation factor 1 alpha 1 |
affects binding |
EXP |
Gamendazole binds to Eef1a1 protein |
RGD |
PMID:18218611 |
RGD:10401123 |
NCBI chr 8:79,341,554...79,344,784
Ensembl chr 8:79,341,557...79,344,839
|
|
G |
Hsp90ab1 |
heat shock protein 90 alpha family class B member 1 |
affects binding |
EXP |
gamendazole binds to Hsp90ab1 protein |
RGD |
PMID:18218611 |
RGD:10401123 |
NCBI chr 9:15,432,986...15,438,358
Ensembl chr 9:15,433,691...15,438,488
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions decreases activity |
ISO |
Glipizide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Glipizide results in decreased activity of ABCB11 protein |
CTD |
PMID:24014644 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
decreases activity |
ISO |
Glipizide results in decreased activity of AKR1C1 protein |
CTD |
PMID:26362498 |
|
NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
decreases activity |
ISO |
Glipizide results in decreased activity of AKR1C2 protein |
CTD |
PMID:26362498 |
|
NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
decreases activity |
ISO |
Glipizide results in decreased activity of AKR1C3 protein |
CTD |
PMID:26362498 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions increases expression decreases activity |
ISO EXP |
[Glyburide results in decreased activity of ABCB11 protein] which results in decreased export of Taurodeoxycholic Acid; Glyburide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Glyburide results in increased expression of ABCB11 mRNA [Glyburide results in decreased activity of ABCB11 protein] which results in decreased export of Taurodeoxycholic Acid; [Glyburide results in decreased activity of ABCB11 protein] which results in decreased secretion of Rosuvastatin Calcium |
CTD |
PMID:11343252 PMID:15465654 PMID:15618715 PMID:19853032 PMID:20147439 PMID:20829430 PMID:23956101 PMID:24014644 PMID:27765674 PMID:31348918 More...
|
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
increases expression |
EXP |
Glyburide results in increased expression of ABCB4 mRNA |
CTD |
PMID:27765674 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases activity |
ISO |
Glyburide results in decreased activity of ABCC1 protein |
CTD |
PMID:15652236 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression |
EXP |
Glyburide results in increased expression of ABCC2 mRNA |
CTD |
PMID:27765674 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression |
EXP |
Glyburide results in increased expression of ABCC3 mRNA |
CTD |
PMID:27765674 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcc8 |
ATP binding cassette subfamily C member 8 |
increases response to substance affects binding multiple interactions |
EXP |
ABCC8 protein results in increased susceptibility to Glyburide Glyburide binds to ABCC8 protein; Glyburide binds to ABCC8 protein mutant form Adenosine Triphosphate deficiency inhibits the reaction [Estradiol inhibits the reaction [Glyburide binds to ABCC8 protein]]; Estradiol inhibits the reaction [Glyburide binds to ABCC8 protein mutant form]; Estradiol inhibits the reaction [Glyburide binds to ABCC8 protein]; resveratrol inhibits the reaction [Glyburide binds to ABCC8 protein] |
CTD |
PMID:17138562 PMID:19095654 |
|
NCBI chr 1:96,598,663...96,679,495
Ensembl chr 1:96,598,647...96,679,510
|
|
G |
Abcc9 |
ATP binding cassette subfamily C member 9 |
affects binding decreases activity multiple interactions |
ISO |
Glyburide binds to ABCC9 protein mutant form Glyburide results in decreased activity of ABCC9 protein [Glyburide results in decreased activity of ABCC9 protein] which results in increased expression of XDH protein; Estradiol inhibits the reaction [Glyburide binds to ABCC9 protein mutant form]; Glyburide inhibits the reaction [[Oligomycins co-treated with Deoxyglucose] results in increased activity of [KCNJ11 protein binds to ABCC9 protein]]; resveratrol inhibits the reaction [Glyburide binds to ABCC9 protein] |
CTD |
PMID:17138562 PMID:19095654 PMID:22622455 PMID:28842488 |
|
NCBI chr 4:175,531,854...175,655,849
Ensembl chr 4:175,532,547...175,655,356
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions increases export decreases export |
ISO |
3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester inhibits the reaction [ABCG2 protein results in increased export of Glyburide]; 3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester promotes the reaction [ABCG2 protein polymorphism results in decreased export of Glyburide]; Genistein inhibits the reaction [ABCG2 protein results in increased export of Glyburide]; Genistein promotes the reaction [ABCG2 protein polymorphism results in decreased export of Glyburide] |
CTD |
PMID:26850786 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
increases expression |
EXP |
Glyburide results in increased expression of ABCG5 mRNA |
CTD |
PMID:27765674 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Ace2 |
angiotensin I converting enzyme 2 |
decreases expression |
ISO |
Glyburide results in decreased expression of ACE2 mRNA |
CTD |
PMID:32808185 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP |
Glyburide promotes the reaction [Isoproterenol results in increased expression of ACTA2 protein]; pyrvinium inhibits the reaction [Glyburide promotes the reaction [Isoproterenol results in increased expression of ACTA2 protein]] |
CTD |
PMID:35305975 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
Glyburide inhibits the reaction [Tetrachlorodibenzodioxin binds to AHR protein] |
CTD |
PMID:10799337 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Aif1 |
allograft inflammatory factor 1 |
multiple interactions |
EXP ISO |
Glyburide inhibits the reaction [2,5-hexanedione results in increased expression of AIF1 protein] Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of AIF1 protein] |
CTD |
PMID:32375810 PMID:32522579 PMID:32860822 |
|
NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
decreases activity |
ISO |
Glyburide results in decreased activity of AKR1C1 protein |
CTD |
PMID:26362498 |
|
NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
decreases activity |
ISO |
Glyburide results in decreased activity of AKR1C2 protein |
CTD |
PMID:26362498 |
|
NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
decreases activity |
ISO |
Glyburide results in decreased activity of AKR1C3 protein |
CTD |
PMID:26362498 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
Glyburide inhibits the reaction [sodium bisulfide results in increased phosphorylation of AKT1 protein]; Glyburide inhibits the reaction [Streptozocin results in decreased expression of AKT1 protein] |
CTD |
PMID:21800153 PMID:33724628 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
affects binding |
ISO |
Glyburide binds to ALB protein |
CTD |
PMID:20974553 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Apoa1 |
apolipoprotein A1 |
multiple interactions |
ISO |
Glyburide promotes the reaction [1,2-linoleoylphosphatidylcholine results in increased secretion of APOA1 protein]; Glyburide promotes the reaction [Clofibrate results in increased secretion of APOA1 protein] |
CTD |
PMID:19717637 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Arg1 |
arginase 1 |
multiple interactions |
EXP ISO |
Glyburide inhibits the reaction [2,5-hexanedione results in decreased expression of ARG1 mRNA] Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of ARG1 mRNA] |
CTD |
PMID:32522579 PMID:32860822 PMID:34052309 |
|
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
Glyburide inhibits the reaction [Streptozocin results in increased expression of BAX protein] |
CTD |
PMID:33724628 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
Glyburide inhibits the reaction [sodium bisulfide results in increased expression of BCL2 protein]; Glyburide inhibits the reaction [Streptozocin results in decreased expression of BCL2 protein] |
CTD |
PMID:21800153 PMID:33724628 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Capn2 |
calpain 2 |
increases expression |
ISO |
Glyburide results in increased expression of CAPN2 mRNA |
CTD |
PMID:33652124 |
|
NCBI chr13:94,150,244...94,200,969
Ensembl chr13:94,150,240...94,200,969
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
EXP ISO |
Glyburide inhibits the reaction [2,5-hexanedione results in increased cleavage of CASP1 protein]; Glyburide inhibits the reaction [Paraquat results in increased expression of CASP1 protein] Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased cleavage of CASP1 protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased cleavage of CASP1 protein]; Glyburide inhibits the reaction [Ozone results in increased cleavage of CASP1 protein] |
CTD |
PMID:25338942 PMID:32167222 PMID:32375810 PMID:32522579 PMID:32860822 PMID:34052309 More...
|
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity increases expression |
EXP ISO |
Glyburide inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased activity of CASP3 protein]; Glyburide promotes the reaction [Isoproterenol results in increased activity of CASP3 protein]; pyrvinium inhibits the reaction [Glyburide promotes the reaction [Isoproterenol results in increased activity of CASP3 protein]] Glyburide results in increased activity of CASP3 protein Glyburide results in increased expression of CASP3 mRNA |
CTD |
PMID:16310184 PMID:33652124 PMID:35305975 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions |
ISO EXP |
Glyburide inhibits the reaction [Streptozocin results in decreased expression of CAT protein] Glyburide inhibits the reaction [Streptozocin results in decreased activity of CAT protein]; Glyburide inhibits the reaction [Streptozocin results in decreased expression of CAT protein]; Glyburide promotes the reaction [Isoproterenol results in decreased activity of CAT protein]; pyrvinium inhibits the reaction [Glyburide promotes the reaction [Isoproterenol results in decreased activity of CAT protein]] |
CTD |
PMID:23716880 PMID:24760747 PMID:26700463 PMID:26748309 PMID:28757134 PMID:29223569 PMID:30582900 PMID:30817903 PMID:33724628 PMID:35305975 More...
|
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cftr |
CF transmembrane conductance regulator |
multiple interactions decreases activity |
ISO EXP |
Glyburide binds to and results in decreased activity of CFTR protein; Glyburide inhibits the reaction [1-Octanol results in increased activity of CFTR protein]; Glyburide inhibits the reaction [[[Colforsin co-treated with Genistein] results in increased activity of CFTR protein] which results in increased transport of Iodides]; Glyburide inhibits the reaction [Colforsin results in increased activity of CFTR protein] Glyburide results in decreased activity of CFTR protein Glyburide inhibits the reaction [[Phenylephrine co-treated with 5-butyl-6-hydroxy-10-chlorobenzo(c)quinolizinium chloride] results in increased activity of CFTR protein] Glyburide inhibits the reaction [CFTR protein affects the transport of Bicarbonates]; Glyburide inhibits the reaction [CFTR protein affects the transport of Chlorides] |
CTD |
PMID:14502435 PMID:14967738 PMID:15131065 PMID:15236628 PMID:15371258 PMID:15389550 PMID:15634668 PMID:15650130 PMID:15654852 PMID:15802612 PMID:15857825 PMID:16012949 PMID:16054561 PMID:17596272 PMID:18230692 PMID:19061877 More...
|
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Cp |
ceruloplasmin |
multiple interactions |
EXP |
Glyburide inhibits the reaction [Streptozocin results in decreased expression of CP protein] |
CTD |
PMID:26748309 |
|
NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075
|
|
G |
Cst3 |
cystatin C |
multiple interactions |
EXP |
Glyburide inhibits the reaction [Streptozocin results in increased expression of CST3 protein] |
CTD |
PMID:33387473 |
|
NCBI chr 3:136,336,923...136,340,796
Ensembl chr 3:136,336,920...136,340,822
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
EXP |
[Glyburide co-treated with Isoproterenol] results in increased expression of CTNNB1 mRNA; Glyburide promotes the reaction [Isoproterenol results in increased expression of CTNNB1 protein]; pyrvinium inhibits the reaction [[Glyburide co-treated with Isoproterenol] results in increased expression of CTNNB1 mRNA]; pyrvinium inhibits the reaction [Glyburide promotes the reaction [Isoproterenol results in increased expression of CTNNB1 protein]] |
CTD |
PMID:35305975 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
ISO |
Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CYBB protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYBB protein] |
CTD |
PMID:32375810 PMID:34052309 |
|
NCBI chr X:13,360,583...13,392,517
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
Glyburide inhibits the reaction [Methylcholanthrene results in increased expression of CYP1A1 mRNA]; Glyburide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:10799337 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
EXP |
Glyburide inhibits the reaction [natakalim inhibits the reaction [Isoproterenol results in increased expression of EDN1 mRNA]]; Glyburide inhibits the reaction [natakalim inhibits the reaction [Isoproterenol results in increased expression of EDN1 protein]] |
CTD |
PMID:27890915 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
EXP |
Glyburide promotes the reaction [Isoproterenol results in increased expression of FN1 protein]; pyrvinium inhibits the reaction [Glyburide promotes the reaction [Isoproterenol results in increased expression of FN1 protein]] |
CTD |
PMID:35305975 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fth1 |
ferritin heavy chain 1 |
multiple interactions |
ISO |
Glyburide inhibits the reaction [Lipopolysaccharides results in increased expression of FTH1 mRNA] |
CTD |
PMID:27246103 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
EXP |
Glyburide inhibits the reaction [Streptozocin results in increased activity of G6PC1 protein] |
CTD |
PMID:25641191 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
multiple interactions |
EXP |
Glyburide inhibits the reaction [Streptozocin results in decreased activity of G6PD protein] |
CTD |
PMID:25641191 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
Glyburide inhibits the reaction [Streptozocin results in increased activity of GPT protein] |
CTD |
PMID:29223569 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gsdmd |
gasdermin D |
multiple interactions |
EXP |
Glyburide inhibits the reaction [2,5-hexanedione results in increased cleavage of GSDMD protein] |
CTD |
PMID:32522579 PMID:32860822 |
|
NCBI chr 7:107,542,242...107,547,052
Ensembl chr 7:107,542,083...107,547,055
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
Glyburide inhibits the reaction [Streptozocin results in decreased activity of GSR protein]; Glyburide inhibits the reaction [Streptozocin results in decreased expression of GSR protein] |
CTD |
PMID:26748309 PMID:33724628 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
Glyburide inhibits the reaction [Streptozocin results in increased expression of HMOX1 mRNA] |
CTD |
PMID:30817903 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
Glyburide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Glyburide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of IL12B protein] |
CTD |
PMID:11907163 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
Glyburide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of IL12B protein]; Glyburide inhibits the reaction [Lipopolysaccharides results in increased expression of IL12B protein] |
CTD |
PMID:11907163 |
|
NCBI chr10:28,888,832...28,903,796
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il17a |
interleukin 17A |
multiple interactions |
EXP |
Glyburide promotes the reaction [Isoproterenol results in increased expression of IL17A protein]; pyrvinium inhibits the reaction [Glyburide promotes the reaction [Isoproterenol results in increased expression of IL17A protein]] |
CTD |
PMID:35305975 |
|
NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
EXP ISO |
Glyburide inhibits the reaction [Paraquat results in increased expression of IL18 protein] Glyburide inhibits the reaction [Ozone results in increased expression of IL18 protein]; Glyburide inhibits the reaction [Paraquat results in increased secretion of IL18 protein] |
CTD |
PMID:25338942 PMID:32167222 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1b |
interleukin 1 beta |
affects secretion multiple interactions |
ISO EXP |
Glyburide affects the secretion of IL1B protein Glyburide inhibits the reaction [2,5-hexanedione results in increased expression of IL1B protein]; Glyburide inhibits the reaction [Paraquat results in increased expression of IL1B protein]; Glyburide inhibits the reaction [Streptozocin results in increased expression of IL1B mRNA]; Glyburide promotes the reaction [Isoproterenol results in increased expression of IL1B protein]; pyrvinium inhibits the reaction [Glyburide promotes the reaction [Isoproterenol results in increased expression of IL1B protein]] Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IL1B protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B protein]; Glyburide inhibits the reaction [Ozone results in increased expression of IL1B protein]; Glyburide inhibits the reaction [Paraquat results in increased secretion of IL1B protein] |
CTD |
PMID:15578659 PMID:25338942 PMID:30817903 PMID:32167222 PMID:32375810 PMID:32522579 PMID:32860822 PMID:34052309 PMID:35305975 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO EXP |
Glyburide inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein] Glyburide inhibits the reaction [Streptozocin results in increased expression of IL6 mRNA]; Glyburide inhibits the reaction [Streptozocin results in increased expression of IL6 protein] |
CTD |
PMID:24760747 PMID:24849676 PMID:26748309 PMID:30817903 PMID:33724628 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins2 |
insulin 2 |
multiple interactions increases response to substance increases secretion increases expression decreases expression |
ISO EXP |
[Glyburide co-treated with Glucose] results in increased expression of INS protein; Glyburide inhibits the reaction [Glucose results in decreased secretion of INS protein]; IRS1 protein polymorphism inhibits the reaction [Glyburide results in increased secretion of INS protein] Glyburide results in increased susceptibility to INS protein Glyburide results in increased expression of INS mRNA Glyburide results in decreased expression of INS protein |
CTD |
PMID:3116364 PMID:10430617 PMID:11305519 PMID:15642492 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions |
ISO |
IRS1 protein polymorphism inhibits the reaction [Glyburide results in increased secretion of INS protein] |
CTD |
PMID:10430617 |
|
NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122
|
|
G |
Irs2 |
insulin receptor substrate 2 |
multiple interactions |
EXP |
Glyburide inhibits the reaction [Streptozocin results in decreased expression of IRS2 protein] |
CTD |
PMID:33724628 |
|
NCBI chr16:78,488,249...78,512,482
Ensembl chr16:78,485,045...78,512,482
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions |
EXP |
Glyburide inhibits the reaction [2,5-hexanedione results in increased expression of ITGAM protein] |
CTD |
PMID:32522579 PMID:32860822 |
|
NCBI chr 1:182,659,047...182,709,495
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Glyburide results in decreased activity of KCNH2 protein |
CTD |
PMID:24052561 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kcnj11 |
potassium inwardly-rectifying channel, subfamily J, member 11 |
multiple interactions decreases response to substance |
ISO |
Glyburide inhibits the reaction [2,4-Dinitrophenol promotes the reaction [KCNJ11 protein results in increased transport of Potassium]]; Glyburide inhibits the reaction [[Oligomycins co-treated with Deoxyglucose] results in increased activity of [KCNJ11 protein binds to ABCC9 protein]] KCNJ11 protein mutant form results in decreased susceptibility to Glyburide |
CTD |
PMID:15949470 PMID:28842488 |
|
NCBI chr 1:96,591,048...96,594,574
Ensembl chr 1:96,591,049...96,594,082
|
|
G |
Kcnj8 |
potassium inwardly-rectifying channel, subfamily J, member 8 |
decreases activity decreases response to substance |
ISO EXP |
Glyburide results in decreased activity of KCNJ8 protein KCNJ8 protein mutant form results in decreased susceptibility to Glyburide |
CTD |
PMID:20050851 PMID:28842488 |
|
NCBI chr 4:175,508,908...175,515,829
Ensembl chr 4:175,508,912...175,515,603
|
|
G |
Kcnk18 |
potassium two pore domain channel subfamily K member 18 |
multiple interactions |
ISO |
Glyburide inhibits the reaction [KCNK18 protein results in increased transport of Potassium] |
CTD |
PMID:12754259 |
|
NCBI chr 1:258,374,671...258,388,945
Ensembl chr 1:258,374,671...258,388,945
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
EXP |
Glyburide inhibits the reaction [Streptozocin results in decreased expression of KEAP1 mRNA] |
CTD |
PMID:30817903 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Lyz2 |
lysozyme 2 |
decreases secretion increases secretion |
ISO |
Glyburide results in decreased secretion of LYZ protein Glyburide results in increased secretion of LYZ protein |
CTD |
PMID:15194485 PMID:15234967 |
|
NCBI chr 7:52,906,810...52,912,154
Ensembl chr 7:52,906,811...52,912,106
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases expression |
EXP |
Quercetin promotes the reaction [Glyburide results in increased expression of MAPK1 protein modified form] |
CTD |
PMID:20860660 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases expression |
EXP |
Quercetin promotes the reaction [Glyburide results in increased expression of MAPK3 protein modified form] |
CTD |
PMID:20860660 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mbp |
myelin basic protein |
multiple interactions |
EXP |
Glyburide inhibits the reaction [2,5-hexanedione results in decreased expression of MBP protein] |
CTD |
PMID:32522579 PMID:32860822 |
|
NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
Glyburide inhibits the reaction [Paraquat results in increased activity of MPO protein]; Glyburide promotes the reaction [Isoproterenol results in increased activity of MPO protein] |
CTD |
PMID:25338942 PMID:35305975 |
|
NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mrc1 |
mannose receptor, C type 1 |
multiple interactions |
EXP |
Glyburide inhibits the reaction [2,5-hexanedione results in decreased expression of MRC1 mRNA] |
CTD |
PMID:32522579 PMID:32860822 |
|
NCBI chr17:77,249,187...77,330,857
Ensembl chr17:77,249,187...77,330,857
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
ISO |
Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NCF1 protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NCF1 protein] |
CTD |
PMID:32375810 PMID:34052309 |
|
NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
|
|
G |
Nefl |
neurofilament light chain |
multiple interactions |
EXP |
Glyburide inhibits the reaction [2,5-hexanedione results in decreased expression of NEFL protein] |
CTD |
PMID:32522579 PMID:32860822 |
|
NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793
|
|
G |
Nfatc1 |
nuclear factor of activated T-cells 1 |
multiple interactions |
ISO |
Glyburide inhibits the reaction [Lipopolysaccharides affects the localization of NFATC1 protein]; Glyburide inhibits the reaction [Lipopolysaccharides promotes the reaction [NFATC1 protein binds to NOS2 promoter]] |
CTD |
PMID:27246103 |
|
NCBI chr18:74,046,421...74,156,041
Ensembl chr18:74,046,904...74,156,028
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
Glyburide inhibits the reaction [Streptozocin results in increased expression of NFE2L2 mRNA] |
CTD |
PMID:30817903 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
EXP ISO |
Glyburide inhibits the reaction [2,5-hexanedione results in increased expression of NLRP3 protein]; Glyburide inhibits the reaction [Paraquat results in increased expression of NLRP3 protein] Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NLRP3 protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NLRP3 protein]; Glyburide inhibits the reaction [Ozone results in increased expression of NLRP3 protein] |
CTD |
PMID:25338942 PMID:32167222 PMID:32375810 PMID:32522579 PMID:32860822 PMID:34052309 More...
|
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO EXP |
Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NOS2 mRNA]; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NOS2 protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 protein]; Glyburide inhibits the reaction [Lipopolysaccharides promotes the reaction [NFATC1 protein binds to NOS2 promoter]]; Glyburide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Glyburide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Glyburide inhibits the reaction [Pinacidil inhibits the reaction [Rotenone results in increased expression of and results in increased activity of NOS2 protein]]; KN 93 inhibits the reaction [Glyburide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]] Glyburide inhibits the reaction [2,5-hexanedione results in increased expression of NOS2 mRNA] |
CTD |
PMID:16257489 PMID:27246103 PMID:32375810 PMID:32522579 PMID:32860822 PMID:34052309 More...
|
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nppb |
natriuretic peptide B |
multiple interactions |
EXP |
Glyburide inhibits the reaction [natakalim inhibits the reaction [Isoproterenol results in increased expression of NPPB mRNA]]; Glyburide inhibits the reaction [natakalim inhibits the reaction [Isoproterenol results in increased expression of NPPB protein]] |
CTD |
PMID:27890915 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
decreases expression |
EXP |
Glyburide results in decreased expression of NR1H4 mRNA |
CTD |
PMID:28391356 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions |
EXP |
Glyburide inhibits the reaction [Streptozocin results in increased expression of PCK1 mRNA] |
CTD |
PMID:20363216 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pklr |
pyruvate kinase L/R |
multiple interactions |
EXP |
Glyburide inhibits the reaction [Streptozocin results in decreased expression of PKLR mRNA] |
CTD |
PMID:20363216 |
|
NCBI chr 2:174,543,008...174,551,863
Ensembl chr 2:174,543,039...174,551,870
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
EXP |
Glyburide inhibits the reaction [Streptozocin results in decreased expression of PPARG mRNA]; Glyburide inhibits the reaction [Streptozocin results in decreased expression of PPARG protein] |
CTD |
PMID:29223569 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
Glyburide inhibits the reaction [Streptozocin results in increased expression of PTGS2 mRNA] |
CTD |
PMID:30817903 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pycard |
PYD and CARD domain containing |
multiple interactions |
EXP |
Glyburide inhibits the reaction [Paraquat results in increased expression of PYCARD protein] |
CTD |
PMID:25338942 |
|
NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Glyburide inhibits the reaction [Streptozocin results in increased expression of RELA mRNA] |
CTD |
PMID:33724628 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
decreases expression |
EXP |
Glyburide results in decreased expression of SLC10A1 mRNA |
CTD |
PMID:27765674 PMID:28391356 |
|
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Slc2a2 |
solute carrier family 2 member 2 |
multiple interactions |
EXP |
Glyburide inhibits the reaction [Streptozocin results in decreased expression of SLC2A2 protein] |
CTD |
PMID:33724628 |
|
NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
EXP |
Glyburide inhibits the reaction [Streptozocin results in decreased expression of SLC2A4 mRNA]; Glyburide inhibits the reaction [Streptozocin results in decreased expression of SLC2A4 protein] |
CTD |
PMID:29223569 PMID:33724628 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc6a3 |
solute carrier family 6 member 3 |
multiple interactions |
ISO |
Glyburide promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC6A3 protein] |
CTD |
PMID:16725203 |
|
NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions |
ISO |
Glyburide inhibits the reaction [SLCO1B3 protein results in increased uptake of Atorvastatin] |
CTD |
PMID:23121773 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
multiple interactions |
ISO |
Glyburide inhibits the reaction [SLCO2B1 protein results in increased uptake of Atorvastatin] |
CTD |
PMID:23121773 |
|
NCBI chr 1:153,959,288...154,007,294
Ensembl chr 1:153,959,293...154,007,353
|
|
G |
Snca |
synuclein alpha |
multiple interactions |
ISO |
Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased phosphorylation of SNCA protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] promotes the reaction [SNCA protein binds to SNCA protein]]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of SNCA protein] |
CTD |
PMID:32375810 PMID:34052309 |
|
NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
Glyburide promotes the reaction [Isoproterenol results in increased expression of TGFB1 protein]; pyrvinium inhibits the reaction [Glyburide promotes the reaction [Isoproterenol results in increased expression of TGFB1 protein]] |
CTD |
PMID:35305975 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
ISO |
Glyburide promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein] |
CTD |
PMID:16725203 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TNF mRNA]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; Glyburide inhibits the reaction [Pinacidil inhibits the reaction [Rotenone results in increased secretion of TNF protein]] Glyburide inhibits the reaction [2,5-hexanedione results in increased expression of TNF mRNA]; Glyburide inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]; Glyburide inhibits the reaction [Streptozocin results in increased expression of TNF protein]; Glyburide promotes the reaction [Isoproterenol results in increased expression of TNF protein]; pyrvinium inhibits the reaction [Glyburide promotes the reaction [Isoproterenol results in increased expression of TNF protein]] |
CTD |
PMID:16257489 PMID:24760747 PMID:26748309 PMID:30817903 PMID:32375810 PMID:32522579 PMID:32860822 PMID:33724628 PMID:34052309 PMID:35305975 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnni3 |
troponin I3, cardiac type |
multiple interactions |
EXP |
Glyburide promotes the reaction [Isoproterenol results in increased expression of TNNI3 protein]; pyrvinium inhibits the reaction [Glyburide promotes the reaction [Isoproterenol results in increased expression of TNNI3 protein]] |
CTD |
PMID:35305975 |
|
NCBI chr 1:69,299,900...69,303,582
Ensembl chr 1:69,299,900...69,303,580
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases expression |
EXP ISO |
Glyburide inhibits the reaction [Streptozocin results in increased expression of TP53 mRNA]; Glyburide inhibits the reaction [Streptozocin results in increased expression of TP53 protein] Glyburide results in increased expression of TP53 mRNA |
CTD |
PMID:30817903 PMID:33387473 PMID:33652124 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Trpm4 |
transient receptor potential cation channel, subfamily M, member 4 |
decreases activity |
EXP ISO |
Glyburide results in decreased activity of TRPM4 protein |
CTD |
PMID:16966582 PMID:17188667 |
|
NCBI chr 1:95,781,805...95,812,095
Ensembl chr 1:95,782,000...95,812,532
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
ISO |
[Glyburide results in decreased activity of ABCC9 protein] which results in increased expression of XDH protein |
CTD |
PMID:22622455 |
|
NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases phosphorylation |
ISO |
IC 87114 inhibits the reaction [IL4 protein results in increased phosphorylation of AKT1 protein] IC 87114 results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:16179367 PMID:19176369 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
IC 87114 inhibits the reaction [PTPN11 protein mutant form results in increased susceptibility to CSF2 protein] |
CTD |
PMID:22315502 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions decreases phosphorylation |
ISO |
IC 87114 inhibits the reaction [IL4 protein results in increased phosphorylation of FOXO3 protein] IC 87114 results in decreased phosphorylation of FOXO3 protein |
CTD |
PMID:16179367 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Gsk3a |
glycogen synthase kinase 3 alpha |
decreases phosphorylation |
ISO |
IC 87114 results in decreased phosphorylation of GSK3A protein |
CTD |
PMID:16179367 |
|
NCBI chr 1:80,815,843...80,825,732
Ensembl chr 1:80,815,850...80,825,802
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
decreases phosphorylation |
ISO |
IC 87114 results in decreased phosphorylation of GSK3B protein |
CTD |
PMID:16179367 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
IC 87114 inhibits the reaction [Toluene 2,4-Diisocyanate results in decreased secretion of IL10 protein] |
CTD |
PMID:33711354 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO |
IC 87114 inhibits the reaction [Toluene 2,4-Diisocyanate results in increased secretion of IL18 protein] |
CTD |
PMID:33711354 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
IC 87114 inhibits the reaction [IL4 protein results in increased phosphorylation of AKT1 protein]; IC 87114 inhibits the reaction [IL4 protein results in increased phosphorylation of FOXO3 protein]; IC 87114 inhibits the reaction [IL4 protein results in increased phosphorylation of MAPK1 protein]; IC 87114 inhibits the reaction [IL4 protein results in increased phosphorylation of MAPK3 protein]; IC 87114 inhibits the reaction [Toluene 2,4-Diisocyanate results in increased secretion of IL4 protein] |
CTD |
PMID:16179367 PMID:33711354 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il5 |
interleukin 5 |
multiple interactions |
ISO |
IC 87114 inhibits the reaction [Toluene 2,4-Diisocyanate results in increased secretion of IL5 protein] |
CTD |
PMID:33711354 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
IC 87114 inhibits the reaction [Toluene 2,4-Diisocyanate results in increased secretion of IL6 protein] |
CTD |
PMID:33711354 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions decreases phosphorylation |
ISO |
IC 87114 inhibits the reaction [IL4 protein results in increased phosphorylation of MAPK1 protein] IC 87114 results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:16179367 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases phosphorylation |
ISO |
IC 87114 inhibits the reaction [IL4 protein results in increased phosphorylation of MAPK3 protein] IC 87114 results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:16179367 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Pik3cd |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta |
decreases activity multiple interactions |
ISO |
IC 87114 results in decreased activity of PIK3CD protein IC 87114 inhibits the reaction [Toluene 2,4-Diisocyanate results in increased expression of PIK3CD protein] |
CTD |
PMID:16179367 PMID:33711354 |
|
NCBI chr 5:160,094,952...160,142,962
Ensembl chr 5:160,094,952...160,120,930
|
|
G |
Pik3cg |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma |
multiple interactions |
ISO |
IC 87114 inhibits the reaction [Toluene 2,4-Diisocyanate results in increased expression of PIK3CG protein] |
CTD |
PMID:33711354 |
|
NCBI chr 6:48,766,778...48,802,098
Ensembl chr 6:48,766,864...48,802,043
|
|
G |
Ptpn11 |
protein tyrosine phosphatase, non-receptor type 11 |
multiple interactions increases response to substance |
ISO |
IC 87114 inhibits the reaction [PTPN11 protein mutant form results in increased susceptibility to CSF2 protein] PTPN11 protein mutant form results in increased susceptibility to IC 87114 |
CTD |
PMID:22315502 |
|
NCBI chr12:35,365,436...35,424,925
Ensembl chr12:35,383,144...35,424,925
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
decreases phosphorylation |
ISO |
IC 87114 results in decreased phosphorylation of RPS6KB1 protein |
CTD |
PMID:16179367 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases phosphorylation |
ISO |
2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [[idelalisib co-treated with FASLG protein] results in decreased phosphorylation of AKT1 protein]; [idelalisib co-treated with FASLG protein] results in decreased phosphorylation of AKT1 protein; palbociclib promotes the reaction [idelalisib results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:23676220 PMID:31445927 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [[FASLG protein co-treated with idelalisib] results in increased expression of and affects the localization of BAX protein]; [FASLG protein co-treated with idelalisib] results in increased expression of and affects the localization of BAX protein |
CTD |
PMID:31445927 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [[FASLG protein co-treated with idelalisib] results in decreased expression of BCL2 protein]; [FASLG protein co-treated with idelalisib] results in decreased expression of BCL2 protein |
CTD |
PMID:31445927 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
ISO |
2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [[FASLG protein co-treated with idelalisib] results in decreased expression of BCL2L1 protein]; [FASLG protein co-treated with idelalisib] results in decreased expression of BCL2L1 protein |
CTD |
PMID:31445927 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
ISO |
2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [[FASLG protein co-treated with idelalisib] results in increased cleavage of BID protein]; [FASLG protein co-treated with idelalisib] results in increased cleavage of BID protein |
CTD |
PMID:31445927 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[palbociclib results in increased susceptibility to idelalisib] which results in increased cleavage of CASP3 protein |
CTD |
PMID:23676220 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [[TNF protein co-treated with idelalisib] results in increased activity of CASP8 protein]; 2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [idelalisib promotes the reaction [FASLG protein results in increased cleavage of CASP8 protein]]; [TNF protein co-treated with idelalisib] results in increased activity of CASP8 protein; idelalisib promotes the reaction [FASLG protein results in increased cleavage of CASP8 protein] |
CTD |
PMID:31445927 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
multiple interactions |
ISO |
2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [[FASLG protein co-treated with idelalisib] results in decreased expression of CFLAR protein]; 2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [[TNF protein co-treated with idelalisib] results in decreased expression of CFLAR protein]; [FASLG protein co-treated with idelalisib] results in decreased expression of CFLAR protein; [TNF protein co-treated with idelalisib] results in decreased expression of CFLAR protein |
CTD |
PMID:31445927 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
decreases expression |
ISO |
idelalisib decreases expression of Cxcl1 protein in liver and spleen |
RGD |
PMID:27999013 |
RGD:40890273 |
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Fas |
Fas cell surface death receptor |
affects response to substance multiple interactions |
ISO |
idelalisib affects the susceptibility to FAS protein FAS protein affects the reaction [idelalisib results in increased expression of ALT protein] |
CTD |
PMID:31445927 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO |
2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [[FASLG protein co-treated with idelalisib] results in decreased expression of BCL2 protein]; 2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [[FASLG protein co-treated with idelalisib] results in decreased expression of BCL2L1 protein]; 2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [[FASLG protein co-treated with idelalisib] results in decreased expression of CFLAR protein]; 2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [[FASLG protein co-treated with idelalisib] results in increased cleavage of BID protein]; 2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [[FASLG protein co-treated with idelalisib] results in increased expression of and affects the localization of BAX protein]; 2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [[idelalisib co-treated with FASLG protein] results in decreased phosphorylation of AKT1 protein]; 2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [idelalisib inhibits the reaction [FASLG protein results in increased phosphorylation of RELA protein]]; 2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [idelalisib promotes the reaction [FASLG protein results in increased cleavage of CASP8 protein]]; [FASLG protein co-treated with idelalisib] results in decreased expression of BCL2 protein; [FASLG protein co-treated with idelalisib] results in decreased expression of BCL2L1 protein; [FASLG protein co-treated with idelalisib] results in decreased expression of CFLAR protein; [FASLG protein co-treated with idelalisib] results in increased cleavage of BID protein; [FASLG protein co-treated with idelalisib] results in increased expression of and affects the localization of BAX protein; [idelalisib co-treated with FASLG protein] results in decreased phosphorylation of AKT1 protein; idelalisib inhibits the reaction [FASLG protein results in increased phosphorylation of RELA protein]; idelalisib promotes the reaction [FASLG protein results in increased cleavage of CASP8 protein] |
CTD |
PMID:31445927 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions affects expression increases expression |
ISO |
[Galactosamine co-treated with Lipopolysaccharides] promotes the reaction [idelalisib results in increased expression of ALT protein]; FAS protein affects the reaction [idelalisib results in increased expression of ALT protein] idelalisib affects the expression of GPT protein |
CTD |
PMID:31445927 PMID:31501888 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases expression multiple interactions |
ISO |
idelalisib results in increased expression of HIF1A protein idelalisib inhibits the reaction [Lipopolysaccharides results in increased expression of HIF1A protein] |
CTD |
PMID:34978009 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Ifng |
interferon gamma |
decreases expression |
ISO |
idelalisib decreases expression of Ifng protein in liver, spleen and lymph node |
RGD |
PMID:27999013 |
RGD:40890273 |
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il10 |
interleukin 10 |
decreases expression |
ISO |
idelalisib decreases expression of Il10 protein in liver, lymph node and spleen |
RGD |
PMID:27999013 |
RGD:40890273 |
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il4 |
interleukin 4 |
decreases expression |
ISO |
idelalisib decreases expression of Il4 protein in lymph node |
RGD |
PMID:27999013 |
RGD:40890273 |
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
decreases expression |
ISO |
idelalisib decreases expression of Il6 protein in liver and spleen |
RGD |
PMID:27999013 |
RGD:40890273 |
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mir122 |
microRNA 122 |
affects expression |
ISO |
idelalisib affects the expression of MIR122 mRNA |
CTD |
PMID:31501888 |
|
NCBI chr18:58,758,703...58,758,787
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions decreases expression |
ISO |
idelalisib inhibits the reaction [Lipopolysaccharides results in increased expression of MMP9 mRNA] idelalisib results in decreased expression of MMP9 protein |
CTD |
PMID:34978009 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
ISO |
idelalisib inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MTOR protein] idelalisib inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MTOR protein]; idelalisib promotes the reaction [Lipopolysaccharides results in increased expression of MTOR mRNA] |
CTD |
PMID:34978009 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
[palbociclib results in increased susceptibility to idelalisib] which results in increased cleavage of PARP1 protein |
CTD |
PMID:23676220 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha |
increases expression multiple interactions |
ISO |
idelalisib results in increased expression of PIK3CA mRNA idelalisib inhibits the reaction [TGFB1 protein results in increased expression of PIK3CA mRNA] |
CTD |
PMID:31522336 |
|
NCBI chr 2:115,175,275...115,249,034
Ensembl chr 2:115,174,984...115,249,032
|
|
G |
Pik3cb |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta |
increases expression multiple interactions |
ISO |
idelalisib results in increased expression of PIK3CB mRNA idelalisib inhibits the reaction [TGFB1 protein results in increased expression of PIK3CB mRNA] |
CTD |
PMID:31522336 |
|
NCBI chr 8:99,594,600...99,699,772
Ensembl chr 8:99,594,644...99,699,663
|
|
G |
Pik3cd |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta |
multiple interactions increases expression |
ISO |
idelalisib inhibits the reaction [TGFB1 protein results in decreased expression of PIK3CD mRNA] idelalisib results in increased expression of PIK3CD mRNA |
CTD |
PMID:31522336 |
|
NCBI chr 5:160,094,952...160,142,962
Ensembl chr 5:160,094,952...160,120,930
|
|
G |
Pik3cg |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma |
decreases expression |
ISO |
idelalisib results in decreased expression of PIK3CG mRNA |
CTD |
PMID:31522336 |
|
NCBI chr 6:48,766,778...48,802,098
Ensembl chr 6:48,766,864...48,802,043
|
|
G |
Pik3ip1 |
phosphoinositide-3-kinase interacting protein 1 |
increases expression |
ISO |
idelalisib results in increased expression of PIK3IP1 mRNA |
CTD |
PMID:23676220 |
|
NCBI chr14:78,203,539...78,216,616
Ensembl chr14:78,204,053...78,216,608
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [idelalisib inhibits the reaction [FASLG protein results in increased phosphorylation of RELA protein]]; idelalisib inhibits the reaction [FASLG protein results in increased phosphorylation of RELA protein] |
CTD |
PMID:31445927 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
idelalisib inhibits the reaction [TGFB1 protein results in decreased expression of PIK3CD mRNA]; idelalisib inhibits the reaction [TGFB1 protein results in increased expression of PIK3CA mRNA]; idelalisib inhibits the reaction [TGFB1 protein results in increased expression of PIK3CB mRNA] |
CTD |
PMID:31522336 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
increases response to substance multiple interactions |
ISO |
idelalisib results in increased susceptibility to TNF protein 2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [[TNF protein co-treated with idelalisib] results in decreased expression of CFLAR protein]; 2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [[TNF protein co-treated with idelalisib] results in increased activity of CASP8 protein]; [TNF protein co-treated with idelalisib] results in decreased expression of CFLAR protein; [TNF protein co-treated with idelalisib] results in increased activity of CASP8 protein |
CTD |
PMID:31445927 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
idelalisib promotes the reaction [Lipopolysaccharides results in increased expression of VEGFA mRNA] idelalisib inhibits the reaction [Lipopolysaccharides results in increased expression of VEGFA mRNA]; idelalisib inhibits the reaction [Lipopolysaccharides results in increased expression of VEGFA protein] |
CTD |
PMID:34978009 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
ISO |
arsenic trioxide inhibits the reaction [lonidamine results in increased phosphorylation of AKT1 protein]; lonidamine promotes the reaction [Curcumin results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:20605902 PMID:21889928 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Aqp9 |
aquaporin 9 |
multiple interactions |
EXP |
lonidamine inhibits the reaction [CFTR protein promotes the reaction [AQP9 protein affects the transport of Water]] |
CTD |
PMID:12606488 |
|
NCBI chr 8:71,797,231...71,837,485
Ensembl chr 8:71,797,234...71,837,395
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
affects localization multiple interactions |
ISO |
lonidamine affects the localization of BAX protein Curcumin promotes the reaction [lonidamine affects the localization of BAX protein]; lonidamine promotes the reaction [Curcumin affects the localization of BAX protein] |
CTD |
PMID:20605902 PMID:21889928 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
BCL2 protein inhibits the reaction [[arsenic trioxide co-treated with lonidamine] results in increased cleavage of and results in increased activity of CASP8 protein]; BCL2 protein inhibits the reaction [arsenic trioxide promotes the reaction [lonidamine results in increased cleavage of and results in increased activity of CASP9 protein]]; BCL2 protein inhibits the reaction [lonidamine promotes the reaction [arsenic trioxide results in increased cleavage of and results in increased activity of CASP9 protein]] |
CTD |
PMID:21889928 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression |
ISO |
lonidamine results in decreased expression of BCL2L1 protein |
CTD |
PMID:21889928 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bid |
BH3 interacting domain death agonist |
increases activity multiple interactions |
ISO |
lonidamine results in increased activity of BID protein [arsenic trioxide co-treated with lonidamine] results in increased cleavage of and results in increased activity of BID protein |
CTD |
PMID:20605902 PMID:21889928 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[arsenic trioxide co-treated with lonidamine] results in increased cleavage of and results in increased activity of CASP3 protein; [Curcumin co-treated with lonidamine] results in increased cleavage of CASP3 protein |
CTD |
PMID:20605902 PMID:21889928 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
[arsenic trioxide co-treated with lonidamine] results in increased cleavage of and results in increased activity of CASP8 protein; BCL2 protein inhibits the reaction [[arsenic trioxide co-treated with lonidamine] results in increased cleavage of and results in increased activity of CASP8 protein] |
CTD |
PMID:21889928 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
[Curcumin co-treated with lonidamine] results in increased cleavage of CASP9 protein; arsenic trioxide promotes the reaction [lonidamine results in increased cleavage of and results in increased activity of CASP9 protein]; BCL2 protein inhibits the reaction [arsenic trioxide promotes the reaction [lonidamine results in increased cleavage of and results in increased activity of CASP9 protein]]; BCL2 protein inhibits the reaction [lonidamine promotes the reaction [arsenic trioxide results in increased cleavage of and results in increased activity of CASP9 protein]]; lonidamine promotes the reaction [arsenic trioxide results in increased cleavage of and results in increased activity of CASP9 protein]; lonidamine results in increased cleavage of and results in increased activity of CASP9 protein |
CTD |
PMID:20605902 PMID:21889928 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cftr |
CF transmembrane conductance regulator |
decreases activity multiple interactions |
ISO EXP |
lonidamine results in decreased activity of CFTR protein lonidamine inhibits the reaction [CFTR protein promotes the reaction [AQP9 protein affects the transport of Water]] |
CTD |
PMID:12606488 PMID:15634668 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Htra2 |
HtrA serine peptidase 2 |
multiple interactions |
ISO |
[lonidamine co-treated with arsenic trioxide] affects the localization of HTRA2 protein |
CTD |
PMID:21889928 |
|
NCBI chr 4:115,556,914...115,560,202
Ensembl chr 4:115,556,916...115,560,095
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
arsenic trioxide inhibits the reaction [lonidamine results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:21889928 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
arsenic trioxide inhibits the reaction [lonidamine results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:21889928 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
decreases expression |
ISO |
lonidamine results in decreased expression of MCL1 protein |
CTD |
PMID:21889928 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Rps6 |
ribosomal protein S6 |
multiple interactions increases phosphorylation |
ISO |
arsenic trioxide inhibits the reaction [lonidamine results in increased phosphorylation of RPS6 protein] |
CTD |
PMID:21889928 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions increases phosphorylation |
ISO |
arsenic trioxide inhibits the reaction [lonidamine results in increased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:21889928 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Stk11 |
serine/threonine kinase 11 |
increases phosphorylation |
ISO |
lonidamine results in increased phosphorylation of STK11 protein |
CTD |
PMID:23041229 |
|
NCBI chr 7:9,574,553...9,591,315
Ensembl chr 7:9,575,269...9,591,315
|
|
G |
Testin |
testin gene |
multiple interactions increases secretion increases expression |
EXP |
adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [lonidamine results in increased expression of TESTIN mRNA]; Cycloheximide inhibits the reaction [lonidamine results in increased expression of TESTIN mRNA]; Cycloheximide inhibits the reaction [lonidamine results in increased secretion of TESTIN protein]; Dactinomycin inhibits the reaction [lonidamine results in increased expression of TESTIN mRNA]; Dactinomycin inhibits the reaction [lonidamine results in increased secretion of TESTIN protein]; lonidamine inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of TESTIN mRNA]; lonidamine inhibits the reaction [Bucladesine results in decreased expression of TESTIN mRNA] lonidamine results in increased expression of TESTIN; lonidamine results in increased expression of TESTIN mRNA |
CTD |
PMID:11090432 |
|
NCBI chr17:3,824,222...3,859,385
Ensembl chr17:3,846,899...3,859,385
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
multiple interactions decreases expression |
ISO |
arsenic trioxide promotes the reaction [lonidamine results in decreased expression of XIAP protein]; Curcumin promotes the reaction [lonidamine results in decreased expression of XIAP protein]; lonidamine promotes the reaction [arsenic trioxide results in decreased expression of XIAP protein]; lonidamine promotes the reaction [Curcumin results in decreased expression of XIAP protein] |
CTD |
PMID:20605902 PMID:21889928 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
decreases expression |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of ABCB1 mRNA; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of ABCB1 protein |
CTD |
PMID:23466342 PMID:27888070 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
multiple interactions decreases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[NFKB1 protein binds to RELA protein] which results in increased expression of ABCB1B mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Curcumin results in decreased expression of ABCB1B protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of ABCB1B protein |
CTD |
PMID:18006147 |
|
NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases expression |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of ABCC1 protein |
CTD |
PMID:27888070 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [erucin results in increased expression of ABCC2 mRNA] |
CTD |
PMID:15896333 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc5 |
ATP binding cassette subfamily C member 5 |
decreases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of ABCC5 protein |
CTD |
PMID:23994249 |
|
NCBI chr11:80,473,809...80,567,257
Ensembl chr11:80,473,872...80,567,253
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in increased expression of ABCG2 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in increased expression of ABCG2 protein] |
CTD |
PMID:21712253 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abl1 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased chemical synthesis of Histamine]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased expression of HDC mRNA] |
CTD |
PMID:16849647 |
|
NCBI chr 3:14,979,853...15,083,065
Ensembl chr 3:14,979,853...15,083,065
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [nickel monoxide analog results in increased expression of ACTA2 protein] |
CTD |
PMID:33895847 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Acvr2b |
activin A receptor type 2B |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [1-Methyl-4-phenylpyridinium affects the expression of ACVR2B mRNA] |
CTD |
PMID:12710931 |
|
NCBI chr 8:119,138,901...119,178,477
Ensembl chr 8:119,138,812...119,170,458
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Carbon Monoxide results in increased expression of ADIPOQ protein] which results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Carbon Monoxide results in increased expression of ADIPOQ protein] which results in increased phosphorylation of NOS3 protein] |
CTD |
PMID:19356108 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Adra1a |
adrenoceptor alpha 1A |
multiple interactions |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[cirazoline results in increased activity of ADRA1A protein] which results in increased transport of Glucose] |
CTD |
PMID:15550506 |
|
NCBI chr15:40,830,125...40,935,902
Ensembl chr15:40,832,534...40,927,500
|
|
G |
Ager |
advanced glycosylation end product-specific receptor |
multiple interactions |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Vitamin A results in increased expression of AGER protein] |
CTD |
PMID:21807062 |
|
NCBI chr20:4,148,150...4,151,361
Ensembl chr20:4,147,890...4,151,078
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [AGT protein results in increased cleavage of SREBF1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [AGT protein results in increased expression of POSTN mRNA] |
CTD |
PMID:15121739 PMID:16325820 PMID:23300732 PMID:25398788 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Ahr |
aryl hydrocarbon receptor |
increases expression multiple interactions decreases expression |
EXP ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of AHR mRNA; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of AHR protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [TGFB1 protein results in increased activity of AHR protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of AHR mRNA |
CTD |
PMID:22406437 PMID:27020609 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B1 |
multiple interactions |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Curcumin results in increased expression of AKR1B1 mRNA] |
CTD |
PMID:17640564 |
|
NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
decreases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of AKR1B10 protein |
CTD |
PMID:23994249 |
|
NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [cadmium acetate results in increased expression of AKR1C3 protein] |
CTD |
PMID:21787718 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases expression decreases reaction decreases phosphorylation multiple interactions decreases expression decreases activity |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of AKT1 protein LY294002 inhibits the reaction [estrogen increases phosphorylation of Akt1 protein] in rat uterus 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of AKT1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Glucose co-treated with Calcitriol] results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [bisphenol F results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cadmium results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [cobaltiprotoporphyrin promotes the reaction [Lipopolysaccharides results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [etoxazole results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [flufenoxuron results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [IL4 protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Isoproterenol results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [LEPR gene mutant form results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Melatonin inhibits the reaction [[nickel chloride results in increased abundance of Nickel] which results in decreased expression of AKT1 mRNA]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Melatonin inhibits the reaction [[nickel chloride results in increased abundance of Nickel] which results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Mercuric Chloride results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Methylmercury Compounds results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Phospholipids results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Quercetin inhibits the reaction [Okadaic Acid results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [RELN protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [SMARCA4A protein inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Temozolomide results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Toluene 2,4-Diisocyanate results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Tretinoin results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [[nickel chloride results in increased abundance of Nickel] which results in decreased expression of AKT1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [[nickel chloride results in increased abundance of Nickel] which results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Arsenic Trioxide results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Dexamethasone results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Melatonin inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased activity of and results in decreased phosphorylation of AKT1 protein; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with HRAS protein] results in decreased phosphorylation of AKT1 protein; [Butyrates co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased phosphorylation of AKT1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of AKT1 mRNA 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the localization of [PDK1 protein binds to AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [1-Methyl-4-phenylpyridinium affects the expression of AKT1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one analog results in decreased expression of and results in decreased phosphorylation of AKT1 protein; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [(4-(((2-(3-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-1,3-thiazol-5-yl)methyl)sulfanyl)-2-methylphenoxy)acetic acid results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [1,3-dichloro-2-propanol results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [2,3',4,4',5-pentachlorobiphenyl results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [4-hydroxyestradiol results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Cholesterol, HDL results in increased phosphorylation of and results in increased activity of AKT1 protein] which results in decreased degradation of NOS3 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Clioquinol co-treated with Copper] results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[FGF7 protein results in increased phosphorylation of AKT1 protein] which results in increased expression of ESR1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[HSPA1A protein co-treated with Formaldehyde] results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[MIR21 mRNA results in decreased susceptibility to Cisplatin] which results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Rosiglitazone co-treated with IAPP protein] results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Acetylcysteine results in increased activity of and results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [arsenite results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [arsenite results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Atrazine results in decreased expression of and results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [BDNF protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [bisphenol A results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cadmium Chloride results in increased cleavage of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Caffeine results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Camptothecin results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Capsaicin results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cholesterol, HDL results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Copper results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Copper Sulfate results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cotinine results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Curcumin results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [cyanoginosin LR results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [DEFA1 protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [DEFA2 protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Diethylhexyl Phthalate results in increased expression of AKT1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Diethylhexyl Phthalate results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Dronabinol results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Endosulfan results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Ethanol results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [FGF2 protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Furazolidone results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [hemistepsin results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [IGF1 protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [INS protein results in increased expression of AKT1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [INS protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [KMUP 1 results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [methanandamide results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [nickel chloride results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [nickel monoxide analog results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Nicotine results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Nicotine results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [NLRC5 protein results in increased expression of AKT1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [NLRC5 protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Oxygen deficiency results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Paclitaxel results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Particulate Matter results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Phosphates results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Polychlorinated Biphenyls analog results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [propazine results in decreased expression of and results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [PTK2 protein promotes the reaction [Doxorubicin results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simazine results in decreased expression of and results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin promotes the reaction [[Nifedipine co-treated with Hydrogen Peroxide] results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spiraeoside inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Temozolomide results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [terbutylazine results in decreased expression of and results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [TGFB1 protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Thapsigargin results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [titanium dioxide results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [TNF protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Tretinoin results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Trichloroethylene results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Ursodeoxycholic Acid results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Vehicle Emissions results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Zinc results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Zinc results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Zinc Sulfate results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Arsenic Trioxide results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Cannabidiol results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [celastrol results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Cisplatin results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [di-n-propyldithiocarbamate results in decreased expression of and results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [fosbretabulin analog results in decreased expression of and results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [kahweol results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Oligopeptides analog results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [polyphenon E results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [rhodojaponin II inhibits the reaction [TNF protein results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [ZH-2 compound results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of and results in decreased phosphorylation of AKT1 protein; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of and results in decreased activity of AKT1 protein; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Benzo(a)pyrene] results in decreased phosphorylation of AKT1 protein; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Estradiol] results in decreased phosphorylation of AKT1 protein; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Quercetin] inhibits the reaction [INS protein results in increased phosphorylation of AKT1 protein]; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Quercetin] results in decreased phosphorylation of AKT1 protein; [Cannabidiol co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased phosphorylation of AKT1 protein; [Doxorubicin co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased phosphorylation of AKT1 protein; [Formaldehyde co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased phosphorylation of AKT1 protein; [PDK1 protein binds to AKT1 protein] inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of AKT1 protein]; [PDK1 protein binds to AKT1 protein] inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of RPS6 protein]; [PDK1 protein binds to AKT1 protein] results in decreased susceptibility to [Paclitaxel co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one]; [PDK1 protein binds to AKT1 protein] which results in decreased susceptibility to 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased phosphorylation of AKT1 protein; [sodium arsenite co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased phosphorylation of AKT1 protein; arsenic disulfide promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of AKT1 protein]; Arsenic Trioxide promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of AKT1 protein]; Cisplatin promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of AKT1 protein]; kahweol promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of AKT1 protein]; polyphenon E promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of AKT1 protein]; Simvastatin promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of AKT1 protein]; Tamoxifen promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of AKT1 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased activity of AKT1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[5-aminoisoquinolinone co-treated with Hydrogen Peroxide] results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Capsaicin co-treated with Oxygen deficiency co-treated with Oxygen] results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Carbon Monoxide results in increased expression of ADIPOQ protein] which results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Selegiline co-treated with 1-Methyl-4-phenylpyridinium] results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cadmium results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cilomilast promotes the reaction [Nitroprusside results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [deuterohemin-alanyl-histidyl-threonyl-valyl-glutamyl-lysine inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [deuterohemin-alanyl-histidyl-threonyl-valyl-glutamyl-lysine results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [diallyl trisulfide inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Doxepin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Ecdysterone promotes the reaction [1-Methyl-4-phenylpyridinium results in increased activity of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Epirubicin results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ferrous sulfate results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rh4 inhibits the reaction [Alloxan results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Glucose results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [GRN protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [IGF1 protein inhibits the reaction [Isoflurane results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [IGF1 protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Iron results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Isoproterenol results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [LHCGR protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Mevinphos results in increased activity of and results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [MT2A protein inhibits the reaction [Tunicamycin results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [NGF protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Quercetin inhibits the reaction [[Dithionite co-treated with Glucose deficiency] results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [rhodioloside inhibits the reaction [Colistin results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Roflumilast promotes the reaction [Nitroprusside results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Rolipram promotes the reaction [Nitroprusside results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvianolic acid B results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Sevoflurane results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Smoke analog results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Thapsigargin results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Triiodothyronine results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Tunicamycin results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Vitamin A results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [[Dithionite co-treated with Glucose deficiency] results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Tunicamycin results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of and results in decreased activity of AKT1 protein; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in decreased phosphorylation of AKT1 protein; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Tretinoin] results in decreased phosphorylation of AKT1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of AKT1 protein |
CTD RGD |
PMID:11306697 PMID:11788791 PMID:12438947 PMID:12511591 PMID:12556562 PMID:12640124 PMID:12710931 PMID:12821261 PMID:12834810 PMID:14755253 PMID:14757120 PMID:14762343 PMID:15001399 PMID:15028728 PMID:15050414 PMID:15177934 PMID:15178407 PMID:15213310 PMID:15339911 PMID:15631803 PMID:15695173 PMID:15845746 PMID:15897870 PMID:15919668 PMID:15956784 PMID:16018989 PMID:16059913 PMID:16168102 PMID:16179367 PMID:16204373 PMID:16211241 PMID:16256798 PMID:16275998 PMID:16288212 PMID:16343977 PMID:16434995 PMID:16472761 PMID:16619521 PMID:16648635 PMID:16682453 PMID:16731823 PMID:16763222 PMID:16973122 PMID:17172471 PMID:17259349 PMID:17324588 PMID:17346750 PMID:17464197 PMID:17513037 PMID:17550345 PMID:17583570 PMID:17623046 PMID:17823925 PMID:17922026 PMID:17962351 PMID:18096819 PMID:18201823 PMID:18276108 PMID:18359480 PMID:18388193 PMID:18622747 PMID:18948619 PMID:19011674 PMID:19038232 PMID:19059400 PMID:19073151 PMID:19139269 PMID:19176369 PMID:19233221 PMID:19299917 PMID:19356108 PMID:19457607 PMID:19561517 PMID:19661335 PMID:19781563 PMID:19814765 PMID:19881297 PMID:19906781 PMID:19956873 PMID:19962417 PMID:20361045 PMID:20386985 PMID:20464445 PMID:20562903 PMID:20600219 PMID:20610540 PMID:20657188 PMID:20658310 PMID:20938987 PMID:21055460 PMID:21138475 PMID:21474332 PMID:21594580 PMID:21655183 PMID:21803128 PMID:21807062 PMID:21820214 PMID:21821001 PMID:21837363 PMID:21976531 PMID:22019741 PMID:22040890 PMID:22046442 PMID:22545124 PMID:22556157 PMID:22687995 PMID:23000059 PMID:23159718 PMID:23285096 PMID:23300809 PMID:23352507 PMID:23453443 PMID:23466500 PMID:23735482 PMID:23793038 PMID:23958495 PMID:24057571 PMID:24122885 PMID:24361488 PMID:24449419 PMID:24462917 PMID:24680926 PMID:24727557 PMID:24875536 PMID:24876378 PMID:24898257 PMID:24946264 PMID:25118938 PMID:25171655 PMID:25203460 PMID:25303017 PMID:25398788 PMID:25471227 PMID:25597859 PMID:25644787 PMID:25773745 PMID:25866362 PMID:26048653 PMID:26089345 PMID:26282490 PMID:26364587 PMID:26506538 PMID:26687534 PMID:26790143 PMID:26942697 PMID:26974319 PMID:27049278 PMID:27050422 PMID:27295300 PMID:27312872 PMID:27338800 PMID:27431321 PMID:27542212 PMID:27658547 PMID:28302560 PMID:28465020 PMID:28756148 PMID:28940008 PMID:29061316 PMID:29186614 PMID:29505745 PMID:29510123 PMID:30205135 PMID:30542770 PMID:30600586 PMID:30726812 PMID:30851366 PMID:31068539 PMID:31445927 PMID:31614463 PMID:31715269 PMID:31743544 PMID:31758290 PMID:31830547 PMID:32044604 PMID:32060308 PMID:32602595 PMID:32613688 PMID:32687844 PMID:32877639 PMID:33131013 PMID:33270355 PMID:33359794 PMID:33450223 PMID:33462182 PMID:33516933 PMID:33581215 PMID:33618463 PMID:33689844 PMID:33771252 PMID:33895847 PMID:34147605 PMID:34784199 PMID:34859534 PMID:34896440 PMID:35122754 PMID:35568058 PMID:35929799 PMID:17272396 More...
|
RGD:152177689 |
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Akt1s1 |
AKT1 substrate 1 |
decreases phosphorylation |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of AKT1S1 protein |
CTD |
PMID:17457363 |
|
NCBI chr 1:95,333,186...95,339,678
Ensembl chr 1:95,332,898...95,339,677
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Calcitriol inhibits the reaction [Glucose results in decreased expression of ALPL protein]] |
CTD |
PMID:33450223 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Angpt1 |
angiopoietin 1 |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ANGPT1 protein inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ANGPT1 protein results in decreased susceptibility to Doxorubicin] |
CTD |
PMID:15763944 |
|
NCBI chr 7:73,528,345...73,783,953
Ensembl chr 7:73,531,486...73,784,067
|
|
G |
Angpt2 |
angiopoietin 2 |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ANGPT2 protein results in decreased expression of BAX protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ANGPT2 protein results in increased expression of BCL2 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ANGPT2 protein results in increased expression of MKI67 protein] |
CTD |
PMID:31838054 |
|
NCBI chr16:71,088,364...71,138,805
Ensembl chr16:71,088,364...71,138,804
|
|
G |
Apln |
apelin |
increases expression multiple interactions increases secretion |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of APLN mRNA 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Eicosapentaenoic Acid results in increased expression of APLN mRNA] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased secretion of APLN protein |
CTD |
PMID:20352620 PMID:21461750 |
|
NCBI chr X:127,180,801...127,213,567
Ensembl chr X:127,203,823...127,213,391
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Clioquinol co-treated with Copper] results in decreased expression of APP protein alternative form] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [coenzyme Q10 results in decreased susceptibility to APP protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased activity of CASP3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lovastatin results in increased secretion of APP protein modified form]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [APP protein modified form results in increased activity of CASP3 protein] |
CTD |
PMID:16648635 PMID:19741129 PMID:22186599 PMID:28756148 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein results in increased expression of AQP3 protein] |
CTD |
PMID:16848764 PMID:18214481 |
|
NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720
|
|
G |
Aqp9 |
aquaporin 9 |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Dihydrotestosterone results in decreased expression of AQP9 mRNA] |
CTD |
PMID:20378617 |
|
NCBI chr 8:71,797,231...71,837,485
Ensembl chr 8:71,797,234...71,837,395
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Capsaicin results in increased expression of AR protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein results in decreased expression of AR protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [methoxyacetic acid promotes the reaction [Testosterone results in increased activity of AR protein]] |
CTD |
PMID:16472761 PMID:18486176 PMID:19059400 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arg2 |
arginase 2 |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Oxygen deficiency results in increased expression of ARG2 protein] |
CTD |
PMID:24951775 |
|
NCBI chr 6:97,936,002...97,961,379
Ensembl chr 6:97,936,002...97,961,378
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cadmium Chloride results in increased expression of ATF4]; Cycloheximide inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cadmium Chloride results in increased expression of ATF4]]; SB 216763 inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cadmium Chloride results in increased expression of ATF4]] |
CTD |
PMID:24057571 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions |
ISO EXP |
[2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with HRAS protein] results in decreased expression of ATF6 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol inhibits the reaction [Cadmium Chloride results in increased expression of ATF6 protein]] |
CTD |
PMID:24898257 PMID:31433112 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atg5 |
autophagy related 5 |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Melatonin inhibits the reaction [[nickel chloride results in increased abundance of Nickel] which results in increased expression of ATG5 mRNA]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [[nickel chloride results in increased abundance of Nickel] which results in increased expression of ATG5 mRNA] |
CTD |
PMID:35568058 |
|
NCBI chr20:47,798,222...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Atg7 |
autophagy related 7 |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Melatonin inhibits the reaction [[nickel chloride results in increased abundance of Nickel] which results in increased expression of ATG7 mRNA]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Melatonin inhibits the reaction [[nickel chloride results in increased abundance of Nickel] which results in increased expression of ATG7 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [[nickel chloride results in increased abundance of Nickel] which results in increased expression of ATG7 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [[nickel chloride results in increased abundance of Nickel] which results in increased expression of ATG7 protein] |
CTD |
PMID:35568058 |
|
NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Genistein results in increased phosphorylation of ATM protein] |
CTD |
PMID:19038232 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Aurkb |
aurora kinase B |
decreases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of AURKB protein |
CTD |
PMID:21530604 |
|
NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837
|
|
G |
Axin2 |
axin 2 |
multiple interactions decreases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Temozolomide results in increased expression of AXIN2 mRNA] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of AXIN2 mRNA |
CTD |
PMID:31758290 |
|
NCBI chr10:93,893,830...93,927,042
Ensembl chr10:93,899,245...93,926,231
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions decreases phosphorylation |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Acrolein results in increased phosphorylation of BAD protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in decreased phosphorylation of BAD protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ursodoxicoltaurine results in increased phosphorylation of and results in decreased activity of BAD protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [polyphenon E results in decreased phosphorylation of BAD protein]; polyphenon E promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of BAD protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [rottlerin inhibits the reaction [trimethyltin results in decreased expression of BAD protein modified form]] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Rotenone results in increased phosphorylation of BAD protein]] |
CTD |
PMID:12438947 PMID:12970779 PMID:14628071 PMID:17123556 PMID:17559149 PMID:19596284 PMID:23285096 PMID:25895139 More...
|
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
affects localization increases expression multiple interactions |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the localization of BAX protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of BAX protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased expression of BAX protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [rottlerin inhibits the reaction [trimethyltin results in increased expression of BAX protein]] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Polyribonucleotides results in decreased expression of MIR141 mRNA] inhibits the reaction [Palmitic Acid results in increased expression of BAX protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in decreased expression of BAX protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol inhibits the reaction [Cadmium Chloride results in increased expression of BAX protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [rhodioloside inhibits the reaction [Colistin results in increased expression of BAX protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvianolic acid B inhibits the reaction [Arsenic Trioxide results in increased expression of BAX protein]] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [Emodin affects the expression of BAX protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ANGPT2 protein results in decreased expression of BAX protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [delphinidin promotes the reaction [TGFB1 results in decreased expression of BAX protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [rebamipide results in decreased expression of BAX protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spiraeoside inhibits the reaction [Glucose results in increased expression of BAX protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [Nitroprusside affects the localization of BAX protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased expression of and results in increased activity of BAX protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Stilbenes analog affects the localization of BAX protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [ZH-2 compound results in increased expression of BAX protein]; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with arsenic disulfide] results in increased expression of BAX protein; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with TNFSF10 protein] results in increased activity of BAX protein; [Arsenic Trioxide co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in increased activity of BAX protein; BCL2 protein inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased expression of and results in increased activity of BAX protein]]; TP53 protein promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased expression of and results in increased activity of BAX protein]] |
CTD |
PMID:15665116 PMID:15942663 PMID:18449500 PMID:20097879 PMID:20386985 PMID:20856197 PMID:22178905 PMID:23201927 PMID:25895139 PMID:27032576 PMID:28465020 PMID:29054700 PMID:29186614 PMID:30365941 PMID:30542770 PMID:31433112 PMID:31838054 PMID:32602595 PMID:32877639 PMID:33689844 PMID:34859534 PMID:34897970 More...
|
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
multiple interactions increases expression |
ISO EXP |
[Doxorubicin co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in increased expression of BBC3 protein; TP53 protein promotes the reaction [[Doxorubicin co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in increased expression of BBC3 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of BBC3 protein |
CTD |
PMID:20856197 PMID:24567336 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression increases expression increases phosphorylation |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [Emodin affects the expression of BCL2 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [amentoflavone inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCL2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ANGPT2 protein results in increased expression of BCL2 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [delphinidin inhibits the reaction [TGFB1 results in decreased expression of BCL2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [rebamipide results in increased expression of BCL2 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Selenium inhibits the reaction [nickel sulfate results in decreased expression of BCL2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spiraeoside inhibits the reaction [Glucose results in decreased expression of BCL2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [ZH-2 compound results in decreased expression of BCL2 protein]; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with arsenic disulfide] results in decreased expression of BCL2 protein; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Tamoxifen] results in decreased expression of BCL2 mRNA; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Tamoxifen] results in decreased expression of BCL2 protein; BCL2 protein inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased cleavage of and results in increased activity of and results in increased localization of BID protein]]; BCL2 protein inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased cleavage of CASP3 protein]]; BCL2 protein inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased cleavage of CASP8 protein]]; BCL2 protein inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased cleavage of CASP9 protein]]; BCL2 protein inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased expression of and results in increased activity of BAX protein]]; BCL2 protein results in decreased susceptibility to [Doxorubicin co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of BCL2 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [5-aminoisoquinolinone inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Polyribonucleotides results in decreased expression of MIR141 mRNA] inhibits the reaction [Palmitic Acid results in decreased expression of BCL2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cadmium results in decreased expression of BCL2 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in increased phosphorylation of BCL2 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Quercetin inhibits the reaction [[Dithionite co-treated with Glucose deficiency] results in decreased expression of BCL2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol inhibits the reaction [Cadmium Chloride results in decreased expression of BCL2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [rhodioloside inhibits the reaction [Colistin results in decreased expression of BCL2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvianolic acid B inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [sodium bisulfide results in increased expression of BCL2 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [[Dithionite co-treated with Glucose deficiency] results in decreased expression of BCL2 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [rottlerin inhibits the reaction [trimethyltin results in decreased expression of BCL2 protein]] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of BCL2 mRNA 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased phosphorylation of BCL2 protein |
CTD |
PMID:16018989 PMID:20386985 PMID:20856197 PMID:21130731 PMID:21800153 PMID:21803128 PMID:22046442 PMID:23201927 PMID:23352507 PMID:25895139 PMID:25955216 PMID:27032576 PMID:28185818 PMID:28465020 PMID:29054700 PMID:29186614 PMID:30365941 PMID:30542770 PMID:31433112 PMID:31838054 PMID:32602595 PMID:32877639 PMID:34612572 PMID:34859534 PMID:34897970 More...
|
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2a1 |
BCL2-related protein A1 |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Butyrates results in increased expression of BCL2A1 mRNA] |
CTD |
PMID:16256798 |
|
NCBI chr 8:89,716,914...89,724,998
Ensembl chr 8:89,716,914...89,724,998
|
|